Cell Biol. – Mol. Carcinogen. --  Cell. Biochem. – Immunol. – Mol. Biol.

Tumor Biol. -- Mol. Genet. – Exp. Ther. – Radiother. – Med. Oncol.

Surg. Oncol. – Diagn. Oncol. – Psychosoc. & Epidemiol. -- Biometrics -- geen  

se-I=cell biol.    (25) 

            (1)                            IF: 4.375                Sectie(s): I
Brecht M; Steenvoorden ACM; Collard JG; Luf S; Erz D; Bartram CR; Janssen JWG. Activation of GEF-h1, a guanine nucleotide exchange factor for RhoA, by DNA transfection. Int J Cancer 2004; 113:533-540.

            (2)                            IF: 30.979               Sectie(s): I
Collard JG. Cancer: Kip moving. Nature 2004; 428(6984):705-708.

            (3)                            IF: 10.456               Sectie(s): VI, I
Engelsma D; Bernad R; Calafat J; Fornerod M. Supraphysiological nuclear export signals bind CRM1 independently of RanGTP and arrest at Nup358. EMBO J 2004; 23:3643-3652.

            (4)                            IF: 6.482                Sectie(s): I
Enserink JM; Price LS; Methi T; Mahic M; Sonnenberg A; Bos JL; Tasken K. The cAMP-Epac-Rap1 pathway regulates cell spreading and cell adhesion to laminin-5 through the alpha3beta1 integrin but not the alpha6beta4 integrin. J Biol Chem 2004; 279(43):44889-44896.

            (5)                            IF: 4.194                Sectie(s): I
Fontao L; Tasanen K; Huber M; Hohl D; Koster J; Bruckner-Tuderman L; Sonnenberg A; Borradori L. Molecular consequences of deletion of the cytoplasmic domain of bullous pemphigoid 180 in a patient with predominant features of epidermolysis bullosa simplex. J Invest Dermatol 2004; 122(1):65-72.

            (6)                            IF: 4.180                Sectie(s): I
Gao Y; Hansson M; Calafat J; Tapper H; Olsson I. Sorting soluble tumor necrosis factor (TNF) receptor for storage and regulated secretion in hematopoietic cells. J Leukoc Biol 2004; 76:870-885.

            (7)                            IF: 4.180                Sectie(s): I
Honing H; Van den Berg TK; Dijkstra CD; Van der Kammen RA; Collard JG; De Vries HE. RhoA activation promotes transendothelial migration of monocytes via ROCK. J Leukoc Biol 2004; 75:523-528.

            (8)                            IF: 7.454                Sectie(s): I
Koster J; Van Wilpe S; Kuikman I; Litjens SHM; Sonnenberg A. Role of binding of plectin to the integrin {beta}4 subunit in the assembly of hemidesmosomes. Mol Biol Cell 2004; 15:1211-1223.

            (9)                            IF: 6.482                Sectie(s): I
Lee S; Varnai P; Balla A; Jalink K; Rhee S; Balla T. The pleckstrin-homology domain of PLCdelta 4 is not critical determinant of the membrane localization of the enzyme. J Biol Chem 2004; 279:24362-24371.

           (10)                            IF: 6.482                Sectie(s): I
Malliri A; Van Es S; Huveneers S; Collard JG. The Rac exchange factor Tiam1 is required for the establishment and maintenance of cadherin-based adhesions. J Biol Chem 2004; 279(29):30092-30098.

           (11)                            IF: 18.913               Sectie(s): VI, I, XIII
Michalides R; Griekspoor A; Balkenende A; Verwoerd D; Janssen L; Jalink K; Floore A; Velds A; Van 't Veer L; Neefjes J. Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer. Cancer Cell 2004; 5(6):597-605.

           (12)                            IF: 4.180                Sectie(s): I
Niemann CU; Cowland JB; Klausen P; Askaa J; Calafat J; Borregaard N. Localization of serglycin in human neutrophil granulocytes and their precursors. J Leukoc Biol 2004; 76(2):406-415.

           (13)                            IF: 6.495                Sectie(s): I
Opdam FJM; Kamp M; De Bruijn R; Roos E. Jak kinase activity is required for lymphoma invasion and metastasis. Oncogene 2004; 23(39):6647-6653.

           (14)                            IF: 7.390                Sectie(s): I, III
Ponsioen B; Zhao J; Riedl J; Zwartkruis F; Van der Krogt G; Zaccolo M; Moolenaar WH; Bos JL; Jalink K. Detecting cAMP-induced Epac activation by fluorescence resonance energy transfer: Epac as a novel cAMP indicator. EMBO Rep 2004; 5:1176-1180.

           (15)                            IF: 6.207                Sectie(s): I
Powelka AM; Sun J; Li J; Gao M; Shaw LM; Sonnenberg A; Hsu VW. Stimulation-dependent recycling of integrin beta1 regulated by ARF6 and Rab11. Traffic 2004; 5(1):20-36.

           (16)                            IF: 6.482                Sectie(s): I
Price LS; Hajdo-Milasinovic A; Zhao J; Zwartkruis FJT; Collard JG; Bos JL. Rap1 regulates E-cadherin-mediated cell-cell adhesion. J Biol Chem 2004; 279(34):35127-35132.

           (17)                            IF: 1.830                Sectie(s): I
Quondamatteo F; Kempkensteffen C; Miosge N; Sonnenberg A; Herken R. Ultrastructural localization of integrin subunits alpha3 and alpha6 in capillarized sinusoids of the human cirrhotic liver. Histol Histopathol 2004; 19(3):799-806.

           (18)                            IF: 2.836                Sectie(s): I
Rosen H; Calafat J; Holmberg L; Olsson I. Sorting of Von Willebrand factor to lysosome-related granules of haematopoietic cells. Biochem Biophys Res Commun 2004; 315(3):671-678.

           (19)                            IF: 3.609                Sectie(s): I
Travis MA; Van der Flier A; Kammerer RA; Mould AP; Sonnenberg A; Humphries MJ. Interaction of filamin A with the integrin beta 7 cytoplasmic domain: role of alternative splicing and phosphorylation. FEBS Lett 2004; 569(1-3):185-190.

           (20)                            IF: 7.250                Sectie(s): I
Uhlenbrock K; Eberth A; Herbrand U; Daryab N; Stege P; Meier F; Collard JG; Ahmadian MR. The RacGEF Tiam1 inhibits migration and invasion of metastatic melanoma via a novel adhesive mechanism. J Cell Sci 2004; 117:4863-4871.

           (21)                            IF: 4.463                Sectie(s): I
Van Rheenen J; Langeslag M; Jalink K. Correcting confocal acquisition to optimize imaging of fluorescence resonance energy transfer by sensitized emission. Biophys J 2004; 86(4):2517-2529.

           (22)                            IF: 6.482                Sectie(s): V, I
Van Vugt MATM; Van de Weerdt BC; Vader G; Janssen H; Calafat J; Klompmaker R; Wolthuis RMF; Medema RH. Polo-like Kinase-1 Is Required for Bipolar Spindle Formation but Is Dispensable for Anaphase Promoting Complex/Cdc20 Activation and Initiation of Cytokinesis. J Biol Chem 2004; 279(35):36841-36854.

           (23)                            IF: 3.694                Sectie(s): VIII, I
Zeamari S; Roos E; Stewart FA. Tumour seeding in peritoneal wound sites in relation to growth-factor expression in early granulation tissue. Eur J Cancer 2004; 40(9):1431-1440.

           (24)                                                    Sectie(s): I
Zeelenberg IS. Chemokine receptor signals: role in migration, invasion and cancer [dissertation]. Amsterdam: University of Amsterdam, 2004 [Dissertation].

           (25)                                           IF: 7.250                    Sectie(s): I
Zimmerman AW; Nelissen JMDT; Van Ernst-de Vries SE; Willems PHGM; De Lange F; Collard JG; Van Leeuwen FN; Figdor CG. Cytoskeletal restraints regulate homotypic ALCAM-mediated adhesion through PKCalpha independently of Rho-like GTPases. J Cell Sci 2004; 117(Pt 13):2841-2852.

se-II=mol.carcinogen.   (16)

            (1)                            IF: 26.494               Sectie(s): II
Bernards R. Wip-ing out cancer [comment]. Nat Genet 2004; 36(4):319-320.

            (2)                            IF: 30.979               Sectie(s): II, VI
Berns K; Hijmans EM; Mullenders J; Brummelkamp TR; Velds A; Heimerikx M; Kerkhoven RM; Madiredjo M; Nijkamp W; Weigelt B; Agami R; Ge W; Cavet G; Linsley PS; Beijersbergen RL; Bernards R. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 2004; 428(6981):431-437.

            (3)                            IF: 14.109               Sectie(s): II
Celie PHN; Van Rossum-Fikkert SE; Van Dijk WJ; Brejc K; Smit AB; Sixma TK. Nicotine and carbamylcholine binding to nicotinic acetylcholine receptors as studied in AChBP crystal structures. Neuron 2004; 41(6):907-914.

            (4)                            IF: 2.208                Sectie(s): II
Cohen S; Morris R; Fernandez F; Ben Jelloul M; Kakaris M; Parthasarathy V; Lamzin V; Kleywegt G; Perrakis A. Towards complete validated models in the next generation of ARP/wARP. Acta Crystallogr D Biol Crystallogr 2004; 60(Pt 12):2222-2229.

            (5)                            IF: 5.225                Sectie(s): II
Das AT; Brummelkamp TR; Westerhout EM; Vink M; Madiredjo M; Bernards R; Berkhout B. Human Immunodeficiency Virus Type 1 Escapes from RNA Interference-Mediated Inhibition. J Virol 2004; 78(5):2601-2605.

            (6)                            IF: 6.495                Sectie(s): II
Edel MJ; Shvarts A; Medema JP; Bernards R. An in vivo functional genetic screen reveals a role for the TRK-T3 oncogene in tumor progression. Oncogene 2004; 23(29):4959-4965.

            (7)                            IF: 3.208                Sectie(s): VIII, IX, II
Kruse JJCM; Te Poele JAM; Velds A; Kerkhoven RM; Boersma LJ; Russell NS; Stewart FA. Identification of differentially expressed genes in mouse kidney after irradiation using microarray analysis. Radiat Res 2004; 161(1):28-38.

            (8)                            IF: 6.482                Sectie(s): II
Lamers MH; Georgijevic D; Lebbink JH; Winterwerp HH; Agianian B; De Wind N; Sixma TK. ATP increases the affinity between MutS ATPase domains; Implications for ATP hydrolysis and conformational changes. J Biol Chem 2004; 279:43879-43885.

            (9)                            IF: 6.495                Sectie(s): II
Logan N; Delavaine L; Graham A; Reilly C; Wilson J; Brummelkamp TR; Hijmans EM; Bernards R; La Thangue NB. E2F-7: a distinctive E2F family member with unusual organization of DNA binding domains. Oncogene 2004; 23:5138-5150.

           (10)                            IF: 1.144                Sectie(s): II
Morris RJ; Zwart PH; Cohen S; Fernandez FJ; Kakaris M; Kirillova O; Vonrhein C; Perrakis A; Lamzin VS. Breaking good resolutions with ARP/wARP. J Synchrotron Rad 2004; 11:56-59.

           (11)                            IF: 11.579               Sectie(s): II
Pichler A; Knipscheer P; Saitoh H; Sixma TK; Melchior F. The RanBP2 SUMO E3 ligase is neither. Nat Struct Mol Biol 2004; 11(10):984-991.

           (12)                            IF: 2.208                Sectie(s): II
Potterton L; McNicholas S; Krissinel E; Gruber J; Cowtan K; Emsley P; Murshudov GN; Cohen S; Perrakis A; Noble M. Developments in the CCP4 molecular-graphics project. Acta Crystallogr D Biol Crystallogr 2004; 60(Pt 12 Pt 1):2288-2294.

           (13)                            IF: 6.482                Sectie(s): II, XIII
Scheijen B; Bronk M; Van der Meer T; De Jong D; Bernards R. High incidence of thymic epithelial tumors in E2F2 transgenic mice. J Biol Chem 2004; 279:10476-10483.

           (14)                            IF: 0.809                Sectie(s): IX, II
Tytgat GNJ; Bartelink H; Bernards R; Giaccone G; Van Lanschot JJB; Offerhaus GJA; Peters GJ. Cancer of the esophagus and gastric cardia: recent advances. Dis Esophagus 2004; 17(1):10-26.

           (15)                            IF: 6.575                Sectie(s): II
Watkins S; Van Pouderoyen G; Sixma TK. Structural analysis of the bipartite DNA-binding domain of Tc3 transposase bound to transposon DNA. Nucleic Acids Res 2004; 32(14):4306-4312.

           (16)                            IF: 5.993                Sectie(s): II
Weichenrieder O; Repanas K; Perrakis A. Crystal structure of the targeting endonuclease of the human LINE-1 retrotransposon. Structure (Camb) 2004; 12(6):975-986.

se-III=cell.biochem.      (26)

            (1)                            IF: 6.495                Sectie(s): III
Baldanzi G; Mitola S; Cutrupi S; Filigheddu N; Van Blitterswijk WJ; Sinigaglia F; Bussolino F; Graziani A. Activation of diacylglycerol kinase alpha is required for VEGF-induced angiogenic signaling in vitro. Oncogene 2004; 23(28):4828-4838.

            (2)                            IF: 7.663                Sectie(s): III
Carvalho RL; Jonker L; Goumans MJ; Larsson J; Bouwman P; Karlsson S; Ten Dijke P; Arthur HM; Mummery CL. Defective paracrine signalling by TGF{beta} in yolk sac vasculature of endoglin mutant mice: a paradigm for hereditary haemorrhagic telangiectasia. Development 2004; 131(24):6237-6247.

            (3)                            IF: 3.160                Sectie(s): III
Chuva De Sousa Lopes SM; Feijen A; Korving J; Korchynskyi O; Larsson J; Karlsson S; Ten Dijke P; Lyons KM; Goldschmeding R; Doevendans P; Mummery CL. Connective tissue growth factor expression and Smad signaling during mouse heart development and myocardial infarction. Dev Dyn 2004; 231:542-550.

            (4)                            IF: 7.390                Sectie(s): III
Divecha N; Halstead JR. Of yeast and men. EMBO Rep 2004; 5(9):865-866.

            (5)                                                    Sectie(s): III, IV
Hendriks JA. Contribution of CD27 and relatives to the specific immune response. Amsterdam: University of Amsterdam, 2004 [Dissertation].

            (6)                            IF: 10.456               Sectie(s): III
Itoh F; Itoh S; Goumans MJ; Valdimarsdottir G; Iso T; Dotto GP; Hamamori Y; Kedes L; Kato M; Ten Dijke P. Synergy and antagonism between Notch and BMP receptor signaling pathways in endothelial cells. EMBO J 2004; 23(3):541-551.

            (7)                            IF: 13.143               Sectie(s): III
Jones DR; Divecha N. Linking lipids to chromatin. Curr Opin Genet Dev 2004; 14(2):196-202.

            (8)                                                    Sectie(s): III
Korchynsky O; Van Bezooijen RL; Ten Dijke P. Bone morphogenetic protein receptors and their nuclear effectors in bone formation. In: Vukicevic C, Sampath K, editors. Basel: Birkhauser, 2004: 9-44.

            (9)                            IF: 10.456               Sectie(s): III
Lebrin F; Goumans MJ; Jonker L; Carvalho RL; Valdimarsdottir G; Thorikay M; Mummery C; Arthur HM; Ten Dijke P. Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction. EMBO J 2004; 23:4018-4028.

           (10)                            IF: 3.510                Sectie(s): III
Los AP; Van Baal J; De Widt J; Divecha N; Van Blitterswijk WJ. Structure-activity relationship of diacylglycerol kinase theta. Biochim Biophys Acta - Mol Cell Biol Lipids 2004; 1636(2-3):169-174.

           (11)                            IF: 3.001                Sectie(s): III
Lutz M; Krieglstein K; Schmitt S; Ten Dijke P; Sebald W; Wizenmann A; Knaus P. Nerve growth factor mediates activation of the Smad pathway in PC12 cells. Eur J Biochem 2004; 271(5):920-931.

           (12)                            IF: 7.250                Sectie(s): III
Monteiro RM; Sousa Lopes SM; Korchynskyi O; Ten Dijke P; Mummery CL. Spatio-temporal activation of Smad1 and Smad5 in vivo: monitoring transcriptional activity of Smad proteins. J Cell Sci 2004; 117(Pt 20):4653-4663.

           (13)                            IF: 6.491                Sectie(s): III
Moolenaar WH; Van Meeteren LA; Giepmans BNG. The ins and outs of lysophosphatidic acid signaling. BioEssays 2004; 26(8):870-881.

           (14)                            IF: 26.626               Sectie(s): III
Motta MC; Divecha N; Lemieux M; Kamel C; Chen D; Gu W; Bultsma Y; McBurney M; Guarente L. Mammalian SIRT1 represses forkhead transcription factors. Cell 2004; 116(4):551-563.

           (15)                            IF: 7.454                Sectie(s): III
Mulder J; Ariaens A; Van den Boomen D; Moolenaar WH. p116Rip Targets Myosin Phosphatase to the Actin Cytoskeleton and Is Essential for RhoA/ROCK-regulated Neuritogenesis. Mol Biol Cell 2004; 15:5516-5527.

           (16)                            IF: 4.101                Sectie(s): III
Piek E; Van Dinther M; Parks WT; Sallee JM; Bottinger EP; Roberts AB; Ten Dijke P. RLP, a novel Ras-like protein, is an immediate-early transforming growth factor-beta (TGF-beta) target gene that negatively regulates transcriptional activity induced by TGF-beta. Biochem J 2004; 383(Pt 1):187-199.

           (17)                            IF: 7.390                Sectie(s): I, III
Ponsioen B; Zhao J; Riedl J; Zwartkruis F; Van der Krogt G; Zaccolo M; Moolenaar WH; Bos JL; Jalink K. Detecting cAMP-induced Epac activation by fluorescence resonance energy transfer: Epac as a novel cAMP indicator. EMBO Rep 2004; 5:1176-1180.

           (18)                            IF: 6.482                Sectie(s): III
Te Vruchte D; Lloyd-Evans E; Veldman RJ; Neville DC; Dwek RA; Platt FM; Van Blitterswijk WJ; Sillence DJ. Accumulation of glycosphingolipids in Niemann-Pick C disease disrupts endosomal transport. J Biol Chem 2004; 279(25):26167-26175.

           (19)                            IF: 14.273               Sectie(s): III
Ten Dijke P; Hill CS. New insights into TGF-beta-Smad signalling. Trends Biochem Sci 2004; 29(5):265-273.

           (20)                                                    Sectie(s): III
Ten Dijke P; Piek E. Receptor serome/threonine kinases. In: Martini L, editor. The encyclopedia of endocrinology and endocrine diseases. Academic Press, 2004: 174-180.

           (21)                                                    Sectie(s): III
Valdimarsdottir G. TGF ß signal transduction in endothelial cells. 2004 [Dissertation].

           (22)                            IF: 15.302               Sectie(s): III
Van Bezooijen RL; Roelen BAJ; Visser A; Van der Wee-Pals L; De Wilt E; Karperien M; Hamersma H; Papapoulos SE; Ten Dijke P; Lowik CWGM. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 2004; 199(6):805-814.

           (23)                                                    Sectie(s): III, IX
Van der Luit AH; Verheij M; Van Blitterswijk WJ. Raft lipid metabolism in relation to alkyl-lysophospholipid-induced apoptosis. In: Mattson MP, editor. Membrane microdomain signaling lipid rafts in biology and medicine. Totowa, NJ, USA: Humana Press, 2004: 91-112.

           (24)                                                    Sectie(s): III
Van Horck FPG. p190RhoGEF and type I PIPkinase: modulators of Rho-mediated neurite remodeling. Leiden: Leiden University, 2004 [Dissertation].

           (25)                            IF: 6.482                Sectie(s): III
Van Meeteren LA; Frederiks F; Giepmans BNG; Fernandes PMF; Billington SJ; Jost BH; Tambourgi DV; Moolenaar W. Spider and Bacterial Sphingomyelinases D Target Cellular Lysophosphatidic Acid Receptors by Hydrolyzing Lysophosphatidylcholine. J Biol Chem 2004; 279(12):10833-10836.

           (26)                            IF: 3.894                Sectie(s): III, IX
Veldman RJ; Zerp S; Van Blitterswijk WJ; Verheij M. N-hexanoyl-sphingomyelin potentiates in vitro doxorubicin cytotoxicity by enhancing its cellular influx. Br J Cancer 2004; 90(4):917-925.

se-IV=immunol.            (18)

           (1)                            IF: 15.302             Sectie(s): IV
Arens R; Schepers K; Nolte MA; Van Oosterwijk MF; Van Lier RAW; Schumacher TNM; Van Oers MHJ. Tumor rejection induced by CD70-mediated quantitative and qualitative effects on effector CD8+ T cell formation. J Exp Med 2004; 199(11):1595-1605.

           (2)                            IF: 6.702               Sectie(s): IV
Bischof F; Hofmann M; Schumacher TNM; Vyth-Dreese FA; Weissert R; Schild H; Kruisbeek AM; Melms A. Analysis of autoreactive CD4 T cells in experimental autoimmune encephalomyelitis after primary and secondary challenge using MHC class II tetramers. J Immunol 2004; 172(5):2878-2884.

           (3)                            IF: 7.008               Sectie(s): IV
Danen-van Oorschot AAAM; Voskamp P; Seelen MCMJ; Van Miltenburg MHAM; Bolk MW; Tait SW; Boesen-de Cock JGR; Rohn JL; Borst J; Noteborn MHM. Human death effector domain-associated factor interacts with the viral apoptosis agonist Apoptin and exerts tumor-preferential cell killing. Cell Death Differ 2004; 11(5):564-573.

           (4)                            IF: 6.482               Sectie(s): IV
De Melker AA; Van der Horst G; Borst J. Ubiquitin ligase activity of c-Cbl guides the EGF receptor into clathrin-coated pits by two distinct modes of Eps15 recruitment. J Biol Chem 2004; 279:55465-55473.

           (5)                            IF: 7.250               Sectie(s): IV
De Melker AA; Van der Horst G; Borst J. c-Cbl directs EGF receptors into an endocytic pathway that involves the ubiquitin-interacting motif of Eps15. J Cell Sci 2004; 117(Pt 21):5001-5012.

           (6)                            IF: 10.120             Sectie(s): IV
De Witte MA; Schumacher TNM. Generating CTL by HLA transplant. Blood 2004; 103:4381-4382.

           (7)                            IF: 15.302             Sectie(s): IV, VII
Hagenbeek TJ; Naspetti M; Malergue F; Garcon F; Nunes JA; Cleutjens KB; Trapman J; Krimpenfort P; Spits H. The Loss of PTEN Allows TCR {alpha}{beta} Lineage Thymocytes to Bypass IL-7 and Pre-TCR-mediated Signaling. J Exp Med 2004; 200(7):883-894.

           (8)                                                    Sectie(s): III, IV
Hendriks JA. Contribution of CD27 and relatives to the specific immune response. Amsterdam: University of Amsterdam, 2004 [Dissertation].

           (9)                            IF: 6.702               Sectie(s): IV
Kessels HWHG; De Visser KE; Tirion FH; Coccoris M; Kruisbeek AM; Schumacher TNM. The impact of self-tolerance on the polyclonal CD8(+) T cell repertoire. J Immunol 2004; 172(4):2324-2331.

         (10)                            IF: 6.702               Sectie(s): IV
Schrama D; Xiang R; Eggert AO; Andersen MH; Pedersen Ls LO; Kampgen E; Schumacher TNM; Reisfeld RR; Becker JC. Shift from systemic to site-specific memory by tumor-targeted IL-2. J Immunol 2004; 172(10):5843-5850.

         (11)                            IF: 7.008               Sectie(s): IV
Tait SWG; Werner AB; De Vries E; Borst J. Mechanism of action of Drosophila Reaper in mammalian cells: reaper globally inhibits protein synthesis and induces apoptosis independent of mitochondrial permeability. Cell Death Differ 2004; 11(8):800-811.

         (12)                            IF: 4.180               Sectie(s): IV
Ten Hove T; The Olle F; Berkhout M; Bruggeman JP; Vyth-Dreese FA; Slors JFM; Van Deventer SJH; Te Velde AA. Expression of CD45RB functionally distinguishes intestinal T lymphocytes in inflammatory bowel disease. J Leukoc Biol 2004; 75(6):1010-1015.

         (13)                            IF: 6.511               Sectie(s): IV, X, BM
Van Oijen M; Bins A; Elias S; Sein J; Weder P; De Gast G; Mallo H; Gallee M; Van Tinteren H; Schumacher T; Haanen J. On the role of melanoma-specific CD8+ T-cell immunity in disease progression of advanced-stage melanoma patients. Clin Cancer Res 2004; 10(14):4754-4760.

         (14)                            IF: 8.649               Sectie(s): IV, X
Verra NCV; Jorritsma A; Weijer K; Ruizendaal JJ; Voordouw A; Weder P; Hooijberg E; Schumacher TNM; Haanen JBAG; Spits H; Luiten RM. Human telomerase reverse transcriptase-transduced human cytotoxic T cells suppress the growth of human melanoma in immunodeficient mice. Cancer Res 2004; 64(6):2153-2161.

         (15)                                                    Sectie(s): IV
Werner AB. Apoptosis signaling to mitochondria by death receptors and DNA damaging anti-cancer regimens. [s.l.]: Universiteit van Amsterdam, 2004 [Dissertation].

         (16)                            IF: 6.482               Sectie(s): IV
Werner AB; Tait SWG; De Vries E; Eldering E; Borst J. Requirement for aspartate-cleaved bid in apoptosis signaling by DNA-damaging anti-cancer regimens. J Biol Chem 2004; 279(27):28771-28780.

         (17)                            IF: 29.162             Sectie(s): IV
Wolkers MC; Brouwenstijn N; Bakker AH; Toebes M; Schumacher TNM. Antigen bias in T cell cross-priming. Science 2004; 304(5675):1314-1317.

         (18)                            IF: 6.702               Sectie(s): IV
Xiao Y; Hendriks J; Langerak P; Jacobs H; Borst J. CD27 is acquired by primed B cells at the centroblast stage and promotes germinal center formation. J Immunol 2004; 172(12):7432-7441.

se-V=mol.biol.  (30)

           (1)                            IF: 26.494             Sectie(s): V
Adams DJ; Biggs PJ; Cox T; Davies R; Van der Weyden L; Jonkers J; Smith J; Plumb B; Taylor R; Nishijima I; Yu Y; Rogers J; Bradley A. Mutagenic insertion and chromosome engineering resource (MICER). Nat Genet 2004; 36(8):867-871.

           (2)                            IF: 6.482               Sectie(s): V
Assem M; Schuetz EG; Leggas M; Sun D; Yasuda K; Reid G; Zelcer N; Adachi M; Strom S; Evans RM; Moore DD; Borst P; Schuetz JD. Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice. J Biol Chem 2004; 279(21):22250-22257.

           (3)                            IF: 3.236               Sectie(s): V
Borst P; Balzarini J; Ono N; Reid G; De Vries H; Wielinga P; Wijnholds J; Zelcer N. The potential impact of drug transporters on nucleoside-analog-based antiviral chemotherapy. Antiviral Res 2004; 62(1):1-7.

           (4)                            IF: 4.279               Sectie(s): V
Borst P; Rottenberg S. Cancer cell death by programmed necrosis? Drug Resist Updat 2004; 7(6):321-324.

           (5)                            IF: 10.456             Sectie(s): V
Bouchard C; Marquardt J; Bras A; Medema RH; Eilers M. Myc-induced proliferation and transformation require Akt-mediated phosphorylation of FoxO proteins. EMBO J 2004; 23(14):2830-2840.

           (6)                            IF: 8.649               Sectie(s): VIII, V, XIII, X
Breedveld P; Zelcer N; Pluim D; Sonmezer O; Tibben MM; Beijnen JH; Schinkel AH; Van Tellingen O; Borst P; Schellens JHM. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res 2004; 64(16):5804-5811.

           (7)                            IF: 6.495               Sectie(s): V
Castedo M; Perfettini J-L; Roumier T; Andreau K; Medema R; Kroemer G. Cell death by mitotic catastrophe: a molecular definition. Oncogene 2004; 23(16):2825-2837.

           (8)                            IF: 6.495               Sectie(s): V
Castedo M; Perfettini JL; Roumier T; Valent A; Raslova H; Yakushijin K; Horne D; Feunteun J; Lenoir G; Medema R; Vainchenker W; Kroemer G. Mitotic catastrophe constitutes a special case of apoptosis whose suppression entails aneuploidy. Oncogene 2004; 23(25):4362-4370.

           (9)                            IF: 6.495               Sectie(s): V
Castedo M; Perfettini J-L; Roumier T; Yakushijin K; Horne D; Medema R; Kroemer G. The cell cycle checkpoint kinase Chk2 is a negative regulator of mitotic catastrophe. Oncogene 2004; 23(25):4353-4361.

         (10)                            IF: 9.635               Sectie(s): V
Chung YJ; Jonkers J; Kitson H; Fiegler H; Humphray S; Scott C; Hunt S; Yu Y; Nishijima I; Velds A; Holstege H; Carter N; Bradley A. A whole-genome mouse BAC microarray with 1-Mb resolution for analysis of DNA copy number changes by array comparative genomic hybridization. Genome Res 2004; 14(1):188-196.

         (11)                            IF: 6.495               Sectie(s): V
Claij N; Te Riele H. Msh2 deficiency does not contribute to cisplatin resistance in mouse embryonic stem cells. Oncogene 2004; 23(1):260-266.

         (12)                            IF: 2.993               Sectie(s): V, VIII
Cummings J; Zelcer N; Allen JD; Yao D; Boyd G; Maliepaard M; Friedberg TH; Smyth JF; Jodrell DI. Glucuronidation as a mechanism of intrinsic drug resistance in colon cancer cells: contribution of drug transport proteins. Biochem Pharmacol 2004; 67(1):31-39.

         (13)                            IF: 17.013             Sectie(s): V
Dannenberg J; Schuijff L; Dekker M; Van der Valk M; Te Riele H. Tissue-specific tumor suppressor activity of retinoblastoma gene homologs p107 and p130. Genes Dev 2004; 18(23):2952-2962.

         (14)                            IF: geen                Sectie(s): V
Hansen JB; Te Riele H; Kristiansen K. Novel function of the retinoblastoma protein in fat: regulation of white versus brown adipocyte differentiation. Cell Cycle 2004; 3(6):774-778.

         (15)                            IF: 10.272             Sectie(s): V
Hansen JB; Jorgensen C; Petersen RK; Hallenborg P; De Matteis R; Boye HA; Petrovic N; Enerback S; Nedergaard J; Cinti S; Te Riele H; Kristiansen K. Retinoblastoma protein functions as a molecular switch determining white versus brown adipocyte differentiation. Proc Natl Acad Sci U S A 2004; 101(12):4112-4117.

         (16)                            IF: 18.913             Sectie(s): V, VII
Jonkers J; Berns A. Oncogene addiction: Sometimes a temporary slavery. Cancer Cell 2004; 6:530-533.

         (17)                            IF: 3.277               Sectie(s): V
Lan L; Hayashi T; Rabeya RM; Nakajima S; Kanno S; Takao M; Matsunaga T; Yoshino M; Ichikawa M; Riele H; Tsuchiya S; Tanaka K; Yasui A. Functional and physical interactions between ERCC1 and MSH2 complexes for resistance to cis-diamminedichloroplatinum(II) in mammalian cells. DNA Repair (Amst) 2004; 3(2):135-143.

         (18)                            IF: 8.142               Sectie(s): V
Leggas M; Adachi M; Scheffer GL; Sun D; Wielinga P; Du G; Mercer KE; Zhuang Y; Panetta JC; Johnston B; Scheper RJ; Stewart CF; Schuetz JD. Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Mol Cell Biol 2004; 24(17):7612-7621.

         (19)                            IF: 4.101               Sectie(s): V
Medema RH. Optimizing RNA interference for application in mammalian cells. Biochem J 2004; 380(Pt 3):593-603.

         (20)                            IF: 8.142               Sectie(s): V, VII
Mikkers H; Nawijn M; Allen J; Brouwer C; Verhoeven E; Jonkers J; Berns A. Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors. Mol Cell Biol 2004; 24(13):6104-6115.

         (21)                            IF: 6.482               Sectie(s): V
Mussmann R; Engstler M; Gerrits H; Kieft R; Bentin Toaldo C; Onderwater J; Koerten H; Van Luenen HG; Borst P. Factors affecting level and localization of the transferrin receptor in Trypanosoma brucei. J Biol Chem 2004; 279:40690-40698.

         (22)                            IF: 8.142               Sectie(s): V
Savouret C; Garcia-Cordier C; Megret J; Te Riele H; Junien C; Gourdon G. MSH2-Dependent Germinal CTG Repeat Expansions Are Produced Continuously in Spermatogonia from DM1 Transgenic Mice. Mol Cell Biol 2004; 24(2):629-637.

         (23)                            IF: 6.482               Sectie(s): V
Tertoolen LGJ; De Vries-Smits LMM; Frye RA; Medema RH; Burgering BMT. FOXO4 is acetylated upon peroxide stress and deacetylated by the longevity protein hSir2(SIRT1). J Biol Chem 2004; 279(28):28873-28879.

         (24)                            IF: 6.495               Sectie(s): VI, V
Theodorou V; Boer M; Weigelt B; Jonkers J; Van der Valk M; Hilkens J. Fgf10 is an oncogene activated by MMTV insertional mutagenesis in mouse mammary tumors and overexpressed in a subset of human breast carcinomas. Oncogene 2004; 23(36):6047-6055.

         (25)                            IF: 3.277               Sectie(s): V
Ulbert S; Eide L; Seeberg E; Borst P. Base J, found in nuclear DNA of Trypanosoma brucei, is not a target for DNA glycosylases. DNA Repair 2004; 3(2):145-154.

         (26)                            IF: 6.482               Sectie(s): VII, V
Van Amerongen R; Van der Gulden H; Bleeker F; Jonkers J; Berns A. Characterization and functional analysis of the murine Frat2 gene. J Biol Chem 2004; 279(26):26967-26974.

         (27)                            IF: 6.482               Sectie(s): V
Van der Horst A; Tertoolen LG; Vries-Smits LM; Frye RA; Medema RH; Burgering BM. FOXO4 is acetylated upon peroxide stress and deacetylated by the longevity protein hSir2(SIRT1). J Biol Chem 2004; 279(28):28873-28879.

         (28)                            IF: 6.482               Sectie(s): V, I
Van Vugt MATM; Van de Weerdt BC; Vader G; Janssen H; Calafat J; Klompmaker R; Wolthuis RMF; Medema RH. Polo-like Kinase-1 Is Required for Bipolar Spindle Formation but Is Dispensable for Anaphase Promoting Complex/Cdc20 Activation and Initiation of Cytokinesis. J Biol Chem 2004; 279(35):36841-36854.

         (29)                            IF: 16.835             Sectie(s): V
Van Vugt MATM; Bras A; Medema RH. Polo-like Kinase-1 Controls Recovery from a G2 DNA Damage-Induced Arrest in Mammalian Cells. Mol Cell 2004; 15(5):799-811.

         (30)                            IF: geen                Sectie(s): V
Van Vugt MATM; Medema RH. Checkpoint Adaptation and Recovery: Back with Polo after the Break. Cell Cycle 2004; 3(11):1383-1386.

se-VI=tumor biol.         (19)

           (1)                            IF: 26.626             Sectie(s): VI
Baas AF; Kuipers J; Van der Wel NN; Batlle E; Koerten HK; Peters PJ; Clevers HC. Complete polarization of single intestinal epithelial cells upon activation of LKB1 by STRAD. Cell 2004; 116(3):457-466.

           (2)                            IF: 8.142               Sectie(s): VI
Bernad R; Van der Velde H; Fornerod M; Pickersgill H. Nup358/RanBP2 attaches to the nuclear pore complex via association with Nup88 and Nup214/CAN and plays a supporting role in CRM1-mediated nuclear protein export. Mol Cell Biol 2004; 24(6):2373-2384.

           (3)                            IF: 30.979             Sectie(s): II, VI
Berns K; Hijmans EM; Mullenders J; Brummelkamp TR; Velds A; Heimerikx M; Kerkhoven RM; Madiredjo M; Nijkamp W; Weigelt B; Agami R; Ge W; Cavet G; Linsley PS; Beijersbergen RL; Bernards R. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 2004; 428(6981):431-437.

           (4)                            IF: 16.016             Sectie(s): VI
Catalfamo M; Karpova T; McNally J; Costes SV; Lockett SJ; Bos E; Peters PJ; Henkart PA. Human CD8+ T cells store RANTES in a unique secretory compartment and release it rapidly after TcR stimulation. Immunity 2004; 20(2):219-230.

           (5)                            IF: 14.807             Sectie(s): VI
Dai J; Li J; Bos E; Porcionatto M; Premont RT; Bourgoin S; Peters PJ; Hsu VW. ACAP1 promotes endocytic recycling by recognizing recycling sorting signals. Dev Cell 2004; 7(5):771-776.

           (6)                            IF: 10.456             Sectie(s): VI, I
Engelsma D; Bernad R; Calafat J; Fornerod M. Supraphysiological nuclear export signals bind CRM1 independently of RanGTP and arrest at Nup358. EMBO J 2004; 23:3643-3652.

           (7)                            IF: 10.456             Sectie(s): VI
Gagrica S; Hauser S; Kolfschoten I; Osterloh L; Agami R; Gaubatz S. Inhibition of oncogenic transformation by mammalian Lin-9, a pRB-associated protein. EMBO J 2004; 23(23):4627-4638.

           (8)                            IF: 6.482               Sectie(s): VI
Griparic L; Van der Wel NN; Orozco IJ; Peters PJ; Van der Bliek AM. Loss of the intermembrane space protein Mgm1/OPA1 induces swelling and localized constrictions along the lengths of mitochondria. J Biol Chem 2004; 279(18):18792-18798.

           (9)                                                    Sectie(s): VI
Harris DA; Peters PJ; Taraboulos A; Lingappa V; DeArmond SJ; Prusiner SB. Cell biology of prions. In: Prusiner SB, editor. Prion biology and diseases. San Francisco: Cold Spring Harbor Press, 2004: 489-544.

         (10)                            IF: 4.175               Sectie(s): VI
Lefman J; Zhang P; Hirai T; Weis RM; Juliani J; Bliss D; Kessel M; Bos E; Peters PJ; Subramaniam S. Three-dimensional electron microscopic imaging of membrane invaginations in Escherichia coli overproducing the chemotaxis receptor Tsr. J Bacteriol 2004; 186(15):5052-5061.

         (11)                            IF: 7.454               Sectie(s): VI
Marsman M; Jordens I; Kuijl C; Janssen L; Neefjes J. Dynein-mediated vesicle transport controls intracellular Salmonella replication. Mol Biol Cell 2004; 15(6):2954-2964.

         (12)                            IF: 18.913             Sectie(s): VI, I, XIII
Michalides R; Griekspoor A; Balkenende A; Verwoerd D; Janssen L; Jalink K; Floore A; Velds A; Van 't Veer L; Neefjes J. Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer. Cancer Cell 2004; 5(6):597-605.

         (13)                            IF: 17.732             Sectie(s): VI
Neefjes J. Fluorescent probes for proteolysis: Tools for drug discovery. Nat Rev Drug Discov 2004; 3(1):58-69.

         (14)                            IF: geen                Sectie(s): VI
Neefjes J; Groothuis TA; Dantuma NP. [The 2004 Nobel Prize in Chemistry for the discovery of ubiquitin-mediated protein degradation]
Nobelprijs Scheikunde 2004 voor de ontdekking van ubiquitine-gemedieerde eiwitafbraak. Ned Tijdschr Geneeskd 2004; 148(52):2579-2582.

         (15)                            IF: 4.536               Sectie(s): VI
Nolte-'t Hoen EN; Wagenaar-Hilbers JP; Peters PJ; Gadella BM; Van Eden W; Wauben MH. Uptake of membrane molecules from T cells endows antigen-presenting cells with novel functional properties. Eur J Immunol 2004.

         (16)                            IF: 16.016             Sectie(s): VI
Reits E; Neijssen J; Herberts C; Benckhuijsen W; Janssen L; Drijfhout JW; Neefjes J. A major role for TPPII in trimming proteasomal degradation products for MHC class I antigen presentation. Immunity 2004; 20(4):495-506.

         (17)                            IF: 6.495               Sectie(s): VI, V
Theodorou V; Boer M; Weigelt B; Jonkers J; Van der Valk M; Hilkens J. Fgf10 is an oncogene activated by MMTV insertional mutagenesis in mouse mammary tumors and overexpressed in a subset of human breast carcinomas. Oncogene 2004; 23(36):6047-6055.

         (18)                            IF: geen                Sectie(s): VI
Voorhoeve PM; Agami R. Unraveling human tumor suppressor pathways: a tale of the INK4A locus. Cell Cycle 2004; 3(5):616-620.

         (19)                            IF: 1.779               Sectie(s): VI
Zhang P; Bos E; Heymann J; Gnaegi H; Kessel M; Peters PJ; Subramaniam S. Direct visualization of receptor arrays in frozen-hydrated sections and plunge-frozen specimens of E. coli engineered to overproduce the chemotaxis receptor Tsr. J Microsc 2004; 216(Pt 1):76-83.

se-VII=mol.genet.         (14)

           (1)                            IF: 26.494             Sectie(s): VII
Auwerx J; Avner P; Baldock R; Ballabio A; Balling R; Barbacid M; Berns A; Bradley A; Brown S; Carmeliet P; Chambon P; Cox R; Davidson D; Davies K; Duboule D; Forejt J; Granucci F; Hastie N; de Angelis MH; Jackson I; Kioussis D; Kollias G; Lathrop M; Lendahl U; Malumbres M; von Melchner H; Muller W; Partanen J; Ricciardi-Castagnoli P; Rigby P; Rosen B; Rosenthal N; Skarnes B; Stewart AF; Thornton J; Tocchini-Valentini G; Wagner E; Wahli W; Wurst W. The European dimension for the mouse genome mutagenesis program. Nat Genet 2004; 36(9):925-927.

           (2)                            IF: 34.833             Sectie(s): VII
Berns A. Good news for gene therapy. N Engl J Med 2004; 350(16):1679-1680.

           (3)                            IF: 6.482               Sectie(s): VII
Carstens MJ; Krempler A; Triplett AA; Van Lohuizen M; Wagner KU. Cell cycle arrest and cell death are controlled by p53-dependent and p53-independent mechanisms in Tsg101-deficient cells. J Biol Chem 2004; 279(34):35984-35994.

           (4)                            IF: 30.979             Sectie(s): VII
Douma S; Van Laar T; Zevenhoven J; Meuwissen R; Van Garderen E; Peeper DS. Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature 2004; 430(7003):1034-1039.

           (5)                            IF: 15.302             Sectie(s): IV, VII
Hagenbeek TJ; Naspetti M; Malergue F; Garcon F; Nunes JA; Cleutjens KB; Trapman J; Krimpenfort P; Spits H. The Loss of PTEN Allows TCR {alpha}{beta} Lineage Thymocytes to Bypass IL-7 and Pre-TCR-mediated Signaling. J Exp Med 2004; 200(7):883-894.

           (6)                            IF: 18.913             Sectie(s): V, VII
Jonkers J; Berns A. Oncogene addiction: Sometimes a temporary slavery. Cancer Cell 2004; 6:530-533.

           (7)                            IF: 30.979             Sectie(s): VII
Leung C; Lingbeek M; Shakhova O; Liu J; Tanger E; Saremaslani P; Van Lohuizen M; Marino S. Bmi1 is essential for cerebellar development and is overexpressed in human medulloblastomas. Nature 2004; 428(6980):337-341.

           (8)                            IF: 18.176             Sectie(s): VII
Lund AH; Van Lohuizen M. Polycomb complexes and silencing mechanisms. Curr Opin Cell Biol 2004; 16(3):239-246.

           (9)                            IF: 17.013             Sectie(s): VII
Lund AH; Van Lohuizen M. Epigenetics and cancer. Genes Dev 2004; 18(19):2315-2335.

         (10)                            IF: 8.142               Sectie(s): V, VII
Mikkers H; Nawijn M; Allen J; Brouwer C; Verhoeven E; Jonkers J; Berns A. Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors. Mol Cell Biol 2004; 24(13):6104-6115.

         (11)                            IF: 6.495               Sectie(s): VII
Robanus-Maandag E; Giovannini M; Van der Valk M; Niwa-Kawakita M; Abramowski V; Antonescu C; Thomas G; Berns A. Synergy of Nf2 and p53 mutations in development of malignant tumours of neural crest origin. Oncogene 2004; 23(39):6541-6547.

         (12)                            IF: 7.663               Sectie(s): VII
Ruiz S; Santos M; Segrelles C; Leis H; Jorcano JL; Berns A; Paramio JM; Vooijs M. Unique and overlapping functions of pRb and p107 in the control of proliferation and differentiation in epidermis. Development 2004; 131(11):2737-2748.

         (13)                            IF: 26.626             Sectie(s): VII
Valk-Lingbeek ME; Bruggeman SWM; Van Lohuizen M. Stem cells and cancer; the polycomb connection. Cell 2004; 118(4):409-418.

         (14)                            IF: 6.482               Sectie(s): VII, V
Van Amerongen R; Van der Gulden H; Bleeker F; Jonkers J; Berns A. Characterization and functional analysis of the murine Frat2 gene. J Biol Chem 2004; 279(26):26967-26974.

se-VIII=exp.ther.           (29)

           (1)                                                    Sectie(s): VIII
Begg AC. Prediction of radiation response. In: Leibel SA, Phillips TL, editors. Textbook of radiation oncology, 2nd ed. Philadelphia: Saunders, 2004: 61-76.

           (2)                            IF: 8.649               Sectie(s): VIII, V, XIII, X
Breedveld P; Zelcer N; Pluim D; Sonmezer O; Tibben MM; Beijnen JH; Schinkel AH; Van Tellingen O; Borst P; Schellens JHM. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res 2004; 64(16):5804-5811.

           (3)                            IF: 2.964               Sectie(s): VIII, IX, XII, XIII
Broeks A; De Witte L; Nooijen A; Huseinovic A; Klijn JGM; Van Leeuwen FE; Russell NS; Van 't Veer LJ. Excess risk for contralateral breast cancer in CHEK2*1100delC germline mutation carriers. Breast Cancer Res Treat 2004; 83(1):91-93.

           (4)                            IF: 2.993               Sectie(s): V, VIII
Cummings J; Zelcer N; Allen JD; Yao D; Boyd G; Maliepaard M; Friedberg TH; Smyth JF; Jodrell DI. Glucuronidation as a mechanism of intrinsic drug resistance in colon cancer cells: contribution of drug transport proteins. Biochem Pharmacol 2004; 67(1):31-39.

           (5)                            IF: 6.511               Sectie(s): VIII, XIII, X, BM
Faneyte IF; Peterse JL; Van Tinteren H; Pronk C; De Vries EGE; Rodenhuis S; Van de Vijver MJ. Predicting early failure after adjuvant chemotherapy in high-risk breast cancer patients with extensive lymph node involvement. Clin Cancer Res 2004; 10(13):4457-4463.

           (6)                            IF: 1.347               Sectie(s): VIII/XIII
Faneyte IF; Kristel PM; Van de Vijver MJ. Multidrug resistance associated genes MRP1, MRP2 and MRP3 in primary and anthracycline exposed breast cancer. Anticancer Res 2004; 24(5A):2931-2939.

           (7)                            IF: 2.870               Sectie(s): VIII, IX, XI
Janssen HL; Hoebers FJP; Sprong D; Goethals L; Williams KJ; Stratford IJ; Haustermans KM; Balm AJM; Begg AC. Differentiation-associated staining with anti-pimonidazole antibodies in head and neck tumors. Radiother Oncol 2004; 70(1):91-97.

           (8)                            IF: 4.337               Sectie(s): VIII
Jonker JW; Schinkel AH. Pharmacological and Physiological Functions of the Polyspecific Organic Cation Transporters: OCT1, 2, and 3 (SLC22A1-3). J Pharmacol Exp Ther 2004; 308(1):2-9.

           (9)                            IF: 3.208               Sectie(s): VIII, IX, II
Kruse JJCM; Te Poele JAM; Velds A; Kerkhoven RM; Boersma LJ; Russell NS; Stewart FA. Identification of differentially expressed genes in mouse kidney after irradiation using microarray analysis. Radiat Res 2004; 161(1):28-38.

         (10)                            IF: 4.285               Sectie(s): VIII, IX
Kruse JJCM; Te Poele JAM; Russell NS; Boersma LJ; Stewart FA. Microarray analysis to identify molecular mechanisms of radiation-induced microvascular damage in normal tissues. Int J Radiat Oncol Biol Phys 2004; 58(2):420-426.

         (11)                            IF: 3.652               Sectie(s): VIII
Mizuno N; Suzuki M; Kusuhara H; Suzuki H; Takeuchi K; Niwa T; Jonker JW; Sugiyama Y. Impaired renal excretion of 6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl) benzothiazole (E3040) sulfate in breast cancer resistance protein (BCRP1/ABCG2) knockout mice. Drug Metab Dispos 2004; 32(9):898-901.

         (12)                            IF: 4.733               Sectie(s): VIII
Perez EA; Pusztai L; Van de Vijver M. Improving patient care through molecular diagnostics. Semin Oncol 2004; 31(5 Suppl 10):14-20.

         (13)                            IF: 2.046               Sectie(s): VIII, X
Pluim D; Van Waardenburg RCAM; Beijnen JH; Schellens JHM. Cytotoxicity of the organic ruthenium anticancer drug Nami-A is correlated with DNA binding in four different human tumor cell lines. Cancer Chemother Pharmacol 2004; 54(1):71-78.

         (14)                            IF: 6.511               Sectie(s): VIII, X
Rademaker-Lakhai JM; Van den Bongard D; Pluim D; Beijnen JH; Schellens JHM. A phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent. Clin Cancer Res 2004; 10(11):3717-3727.

         (15)                            IF: 6.511               Sectie(s): VIII, X
Rademaker-Lakhai JM; Terret C; Howell SB; Baud CM; De Boer RF; Pluim D; Beijnen JH; Schellens JHM; Droz JP. A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors. Clin Cancer Res 2004; 10(10):3386-3395.

         (16)                            IF: 10.864             Sectie(s): VIII, XIII
Rebbeck TR; Friebel T; Lynch HT; Neuhausen SL; Van 't Veer L; Garber JE; Evans GR; Narod SA; Isaacs C; Matloff E; Daly MB; Olopade OI; Weber BL. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004; 22(6):1055-1062.

         (17)                            IF: 4.246               Sectie(s): VIII, X
Sankatsing SU; Beijnen JH; Schinkel AH; Lange JMA; Prins JM. P glycoprotein in human immunodeficiency virus type 1 infection and therapy. Antimicrob Agents Chemother 2004; 48(4):1073-1081.

         (18)                            IF: 5.116               Sectie(s): VIII
Stam RW; van den Heuvel-Eibrink MM; den Boer ML; Ebus ME; Janka-Schaub GE; Allen JD; Pieters R. Multidrug resistance genes in infant acute lymphoblastic leukemia: Ara-C is not a substrate for the breast cancer resistance protein. Leukemia 2004; 18(1):78-83.

         (19)                            IF: 8.649               Sectie(s): VIII
Szabo CI; Schutte M; Broeks A; Houwing-Duistermaat JJ; Thorstenson YR; Durocher F; Oldenburg RA; Wasielewski M; Odefrey F; Thompson D; Floore AN; Kraan J; Klijn JG; Van den Ouweland AM; Wagner TM; Devilee P; Simard J; Van 't Veer LJ; Goldgar DE; Meijers-Heijboer H. Are ATM mutations 7271T-->G and IVS10-6T-->G really high-risk breast cancer-susceptibility alleles? Cancer Res 2004; 64(3):840-843.

         (20)                            IF: 1.929               Sectie(s): VIII
Triesscheijn M; Ruevekamp M; Aalders M; Baas P; Stewart FA. Comparative Sensitivity of Microvascular Endothelial Cells, Fibroblasts and Tumour Cells after in vitro Photodynamic Therapy with mTHPC. Photochem Photobiol 2004; 80:236-241.

         (21)                            IF: 3.894               Sectie(s): VIII, XIII
Van der Hage JA; Van den Broek LJCM; Legrand C; Clahsen PC; Bosch CJA; Robanus-Maandag EC; Van de Velde CJH; Van de Vijver MJ. Overexpression of P70 S6 kinase protein is associated with increased risk of locoregional recurrence in node-negative premenopausal early breast cancer patients. Br J Cancer 2004; 90(8):1543-1550.

         (22)                            IF: 3.201               Sectie(s): VIII, X
Van Waardenburg RCAM; De Jong LA; Van Delft F; Van Eijndhoven MAJ; Bohlander M; Bjornsti MA; Brouwer J; Schellens JHM. Homologous recombination is a highly conserved determinant of the synergistic cytotoxicity between cisplatin and DNA topoisomerase I poisons. Mol Cancer Ther 2004; 3(4):393-402.

         (23)                            IF: 6.482               Sectie(s): VIII, X
Van Waardenburg RCAM; De Jong LA; Van Eijndhoven MAJ; Verseyden C; Pluim D; Jansen LE; Bjornsti MA; Schellens JHM. Platinated DNA adducts enhance poisoning of DNA topoisomerase I by camptothecin. J Biol Chem 2004; 279:54502-54509.

         (24)                            IF: 2.964               Sectie(s): VIII, XII, XIII
Voskuil DW; Bosma A; Vrieling A; Rookus MA; Van 't Veer LJ. Insulin-like growth gactor (IGF)-system mRNA quantities in normal and tumor breast tissue of women with sporadic and familial breast cancer risk. Breast Cancer Res Treat 2004; 84(3):225-233.

         (25)                            IF: 3.894               Sectie(s): VIII, XI, XIII
Weigelt B; Verduijn P; Bosma AJ; Rutgers EJT; Peterse HL; Van 't Veer LJ. Detection of metastases in sentinel lymph nodes of breast cancer patients by multiple mRNA markers. Br J Cancer 2004; 90(8):1531-1537.

         (26)                            IF: geen                Sectie(s): VIII
Weigelt B; Van 't Veer LJ. Hard-wired genotype in metastatic breast cancer. Cell Cycle 2004; 3(6):756-757.

         (27)                            IF: 2.046               Sectie(s): VIII, X
Zamboni WC; Gervais AC; Egorin MJ; Schellens JHM; Zuhowski EG; Pluim D; Joseph E; Hamburger DR; Working PK; Colbern G; Tonda ME; Potter DM; Eiseman JL. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma. Cancer Chemother Pharmacol 2004; 53(4):329-336.

         (28)                            IF: 3.894               Sectie(s): VIII
Zeamari S; Rumping G; Floot B; Lyons S; Stewart FA. In vivo bioluminescence imaging of locally disseminated colon carcinoma in rats. Br J Cancer 2004; 90(6):1259-1264.

         (29)                            IF: 3.694               Sectie(s): VIII, I
Zeamari S; Roos E; Stewart FA. Tumour seeding in peritoneal wound sites in relation to growth-factor expression in early granulation tissue. Eur J Cancer 2004; 40(9):1431-1440.

se-IX=radiother.           (57)

           (1)                            IF: 13.844             Sectie(s): IX, XII
Aleman BMP; Russell NS; Bartelink H; Van Leeuwen FE. Re: Radiation therapy in the treatment of Hodgkin's disease--do you see what I see? [letter]. J Natl Cancer Inst 2004; 96(3):235-236.

           (2)                            IF: 4.285               Sectie(s): IX
Artignan X; Smitsmans MHP; Lebesque JV; Jaffray DA; Van Herk M; Bartelink H. Online ultrasound image guidance for radiotherapy of prostate cancer: impact of image acquisition on prostate displacement. Int J Radiat Oncol Biol Phys 2004; 59(2):595-601.

           (3)                            IF: 1.805               Sectie(s): XI, X, IX, XIII
Balm AJM; Rasch CRN; Schornagel JH; Hilgers FJM; Keus RB; Schultze-Kool L; Ackerstaff AH; Busschers W; Tan IB. High-dose superselective intra-arterial cisplatin and concomitant radiation (RADPLAT) for advanced head and neck cancer. Head Neck 2004; 26(6):485-493.

           (4)                            IF: 6.830               Sectie(s): IX
Bartelink H. Intraoperative radiotherapy for breast cancer: tail wagging the dog? Lancet Oncol 2004; 5(4):207-208.

           (5)                            IF: 4.285               Sectie(s): IX
Belka C; Jendrossek V; Pruschy M; Vink S; Verheij M; Budach W. Apoptosis-modulating agents in combination with radiotherapy-current status and outlook. Int J Radiat Oncol Biol Phys 2004; 58(2):542-554.

           (6)                            IF: 3.694               Sectie(s): X, XII, IX
Boogerd W; Van den Bent MJ; Koehler PJ; Heimans JJ; Van der Sande JJ; Aaronson NK; Hart AAM; Benraadt J; Vecht ChJ. The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study. Eur J Cancer 2004; 40:2726-2733.

           (7)                            IF: 2.305               Sectie(s): IX
Bos LJ; Schwarz M; Bär W; Alber M; Mijnheer BJ; Lebesque JV; Damen EMF. Comparison between manual and automatic segment generation in step-and-shoot IMRT of prostate cancer. Med Phys 2004; 31(1):122-130.

           (8)                            IF: 2.964               Sectie(s): VIII, IX, XII, XIII
Broeks A; De Witte L; Nooijen A; Huseinovic A; Klijn JGM; Van Leeuwen FE; Russell NS; Van 't Veer LJ. Excess risk for contralateral breast cancer in CHEK2*1100delC germline mutation carriers. Breast Cancer Res Treat 2004; 83(1):91-93.

           (9)                            IF: 2.305               Sectie(s): IX
Cho BCJ; Mijnheer BJ; Bartelink H. Determining optimal two-beam axial orientations for heart sparing in left-sided breast cancer patients. Med Phys 2004; 31(1):111-121.

         (10)                                                    Sectie(s): IX
Cho BCJ. Improving radiotherapy treatment for left-sided breast cancer. Amsterdam: Universiteit van Amsterdam, 2004 [Dissertation].

         (11)                            IF: 2.870               Sectie(s): IX
Cho BCJ; Schwarz M; Mijnheer B; Bartelink H. Simplified intensity-modulated radiotherapy using pre-defined segments to reduce cardiac complications in left-sided breast cancer. Radiother Oncol 2004; 70(3):231-241.

         (12)                            IF: 4.285               Sectie(s): IX
De Jaeger K; Seppenwoolde Y; Kampinga HH; Boersma LJ; Belderbos JSA; Lebesque JV. Significance of plasma transforming growth factor-[beta] levels in radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004; 58(5):1378-1387.

         (13)                            IF: 4.285               Sectie(s): IX
De Jaeger K; Seppenwoolde Y; Lebesque JV; Kampinga HH. In reply to Dr. Barthelemy-Brichant [letter]. Int J Radiat Oncol Biol Phys 2004; 60(4):1339-1340.

         (14)                            IF: 4.285               Sectie(s): IX, XI, XIII
Eisbruch A; Schwartz M; Rasch C; Vineberg K; Damen E; Van As CJ; Marsh R; Pameijer FA; Balm AJM. Dysphagia and aspiration after chemoradiotherapy for head-and-neck cancer: which anatomic structures are affected and can they be spared by IMRT? Int J Radiat Oncol Biol Phys 2004; 60(5):1425-1439.

         (15)                            IF: 4.285               Sectie(s): IX, XIII
Haas RLM; De Jong D; Valdés Olmos RA; Hoefnagel CA; Van den Heuvel I; Zerp SF; Bartelink H; Verheij M. In vivo imaging of radiation-induced apoptosis in follicular lymphoma patients. Int J Radiat Oncol Biol Phys 2004; 59(3):782-787.

         (16)                            IF: 18.316             Sectie(s): IX, X
Homs MY; Steyerberg EW; Eijkenboom WMH; Tilanus HW; Stalpers LJ; Bartelsman JF; Van Lanschot JJB; Wijrdeman HK; Mulder CJ; Reinders JG; Boot H; Aleman BMP; Kuipers EJ; Siersema PD. Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial. Lancet 2004; 364(9444):1497-1504.

         (17)                            IF: 2.870               Sectie(s): IX
Hoogeman MS; Van Herk M; De Bois J; Muller-Timmermans P; Koper PC; Lebesque JV. Quantification of local rectal wall displacements by virtual rectum unfolding. Radiother Oncol 2004; 70(1):21-30.

         (18)                            IF: geen                Sectie(s): IX, X, XI
Jansen EPM; Boot H; Cats A; Van Coevorden F; Zoetmulder FAN; Verheij M. [New insights in the adjuvant treatment of gastric cancer]
Nieuwe inzichten in de adjuvante behandeling van het maagcarcinoom. Ned Tijdschr Geneeskd 2004; 148(51):2529-2534.

         (19)                            IF: 2.870               Sectie(s): VIII, IX, XI
Janssen HL; Hoebers FJP; Sprong D; Goethals L; Williams KJ; Stratford IJ; Haustermans KM; Balm AJM; Begg AC. Differentiation-associated staining with anti-pimonidazole antibodies in head and neck tumors. Radiother Oncol 2004; 70(1):91-97.

         (20)                            IF: geen                Sectie(s): IX
Kaanders JHAM; Hoebers FJP; Langendijk JA; Rasch C; Terhaard CHJ; Verheij M; Levendag PC. Nieuwe ontwikkelingen in de radiotherapie van hoofd-hals tumoren: onderzoek in Nederland. Ned Tijdschr Oncol 2004; 1(3):108-114.

         (21)                            IF: 2.870               Sectie(s): XIII, IX,X
Kartachova M; Haas RLM; Valdés Olmos RA; Hoebers FJP; Van Zandwijk N; Verheij M. In vivo imaging of apoptosis by (99m)Tc-Annexin V scintigraphy: visual analysis in relation to treatment response. Radiother Oncol 2004; 72(3):333-339.

         (22)                            IF: 3.694               Sectie(s): XIII, IX, X
Kemper EM; Verheij M; Boogerd W; Beijnen JH; Van Tellingen O. Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein. Eur J Cancer 2004; 40(8):1269-1274.

         (23)                            IF: geen                Sectie(s): X, XI, XIII, IX
Kerst JM; Van Coevorden F; Peterse J; Haas RLM; Linn SC. Jongvolwassenen met Ewing-sarcomen
[Young adults with Ewing's sarcoma]. Ned Tijdschr Geneeskd 2004; 148(27):1355-1358.

         (24)                            IF: 2.305               Sectie(s): XIII, IX
Klein Zeggelink WFA; Hart AAM; Gilhuijs KGA. Assessment of analysis-of-variance-based methods to quantify the random variations of observers in medical imaging measurements: guidelines to the investigator. Med Phys 2004; 31(7):1996-2007.

         (25)                            IF: 4.285               Sectie(s): IX
Koper PCM; Heemsbergen WD; Hoogeman MS; Jansen PP; Hart GAM; Wijnmaalen AJ; Van Os M; Boersma LJ; Lebesque JV; Levendag P. Impact of volume and location of irradiated rectum wall on rectal blood loss after radiotherapy of prostate cancer. Int J Radiat Oncol Biol Phys 2004; 58(4):1072-1082.

         (26)                            IF: 2.870               Sectie(s): IX
Koper PCM; Jansen P; Van Putten W; Van Os M; Wijnmaalen AJ; Lebesque JV; Levendag PC. Gastro-intestinal and genito-urinary morbidity after 3D conformal radiotherapy of prostate cancer: observations of a randomized trial. Radiother Oncol 2004; 73(1):1-9.

         (27)                            IF: 3.208               Sectie(s): VIII, IX, II
Kruse JJCM; Te Poele JAM; Velds A; Kerkhoven RM; Boersma LJ; Russell NS; Stewart FA. Identification of differentially expressed genes in mouse kidney after irradiation using microarray analysis. Radiat Res 2004; 161(1):28-38.

         (28)                            IF: 4.285               Sectie(s): VIII, IX
Kruse JJCM; Te Poele JAM; Russell NS; Boersma LJ; Stewart FA. Microarray analysis to identify molecular mechanisms of radiation-induced microvascular damage in normal tissues. Int J Radiat Oncol Biol Phys 2004; 58(2):420-426.

         (29)                            IF: 2.305               Sectie(s): IX
Lotz HT; Remeijer P; Van Herk M; Lebesque JV; De Bois JA; Zijp LJ; Moonen LM. A model to predict bladder shapes from changes in bladder and rectal filling. Med Phys 2004; 31(6):1415-1423.

         (30)                            IF: 2.305               Sectie(s): IX
Louwe RJW; Tielenburg R; Van Ingen KM; Mijnheer BJ; Van Herk MB. The stability of liquid-filled matrix ionization chamber electronic portal imaging devices for dosimetry purposes. Med Phys 2004; 31(4):819-827.

         (31)                            IF: 2.305               Sectie(s): IX
Louwe RJ; McDermott LN; Sonke J-J; Tielenburg R; Wendling M; Van Herk MB; Mijnheer BJ. The long-term stability of amorphous silicon flat panel imaging devices for dosimetry purposes. Med Phys 2004; 31:2989-2995.

         (32)                            IF: 2.305               Sectie(s): IX
McDermott LN; Louwe RJW; Sonke JJ; Van Herk MB; Mijnheer BJ. Dose-response and ghosting effects of an amorphous silicon electronic portal imaging device. Med Phys 2004; 31(2):285-295.

         (33)                                                    Sectie(s): IX
Meijer GJ. Clinical implementation of high precision radiotherapy for urogenitical tumours [dissertation]. University of Amsterdam, 2004 [Dissertation].

         (34)                                                    Sectie(s): IX
Mijnheer BJ; Olszewska A; Fiorino C; Hartmann G; Knöös T; Rosenwald JC; Welleweerd H. Quality assurance of treatment planning systems - practical examples for non-IMRT photon beams. First edition ESTRO, 2004.

         (35)                            IF: 1.642               Sectie(s): XI, IX, BM
Nieuwenhuijzen JA; Horenblas S; Meinhardt W; Van Tinteren H; Moonen LMF. Salvage cystectomy after failure of interstitial radiotherapy and external beam radiotherapy for bladder cancer. BJU Int 2004; 94(6):793-797.

         (36)                            IF: 3.694               Sectie(s): XI, IX
Nieweg OE; Bartelink H. Implications of lymphatic mapping for staging and adjuvant treatment of patients with breast cancer. Eur J Cancer 2004; 40(2):179-181.

         (37)                            IF: 2.305               Sectie(s): IX
Nijsten SMJJG; Minken AWH; Lambin P; Bruinvis IAD. Verification of treatment parameter transfer by means of electronic portal dosimetry. Med Phys 2004; 31(2):341-347.

         (38)                            IF: 3.574               Sectie(s): XI
Noorda EM; Takkenberg B; Vrouenraets BC; Nieweg OE; Van Geel BN; Eggermont AMM; Hart GAM; Kroon BBR. Isolated limb perfusion prolongs the limb recurrence-free interval after several episodes of excisional surgery for locoregional recurrent melanoma. Ann Surg Oncol 2004; 11(5):491-499.

         (39)                            IF: 2.870               Sectie(s): IX
Poortmans P; Bartelink H; Horiot JC; Struikmans H; Van den Bogaert W; Fourquet A; Jager J; Hoogenraad W; Rodrigus P; Warlam-Rodenhuis C; Collette L; Pierart M. The influence of the boost technique on local control in breast conserving treatment in the EORTC 'boost versus no boost' randomised trial. Radiother Oncol 2004; 72(1):25-33.

         (40)                            IF: 4.285               Sectie(s): IX, XI
Pos FJ; Horenblas S; Lebesque J; Moonen L; Schneider C; Sminia P; Bartelink H. Low-dose-rate brachytherapy is superior to high-dose-rate brachytherapy for bladder cancer. Int J Radiat Oncol Biol Phys 2004; 59(3):696-705.

         (41)                            IF: 4.544               Sectie(s): IX
Russell NS; Bartelink H. Sophisticated radiotherapy with optimal surgery is the way forward. Curr Opin Oncol 2004; 16(6):529-535.

         (42)                            IF: 2.870               Sectie(s): IX
Schwarz M; Lebesque JV; Mijnheer BJ; Damen EMF. Sensitivity of treatment plan optimisation for prostate cancer using the equivalent uniform dose (EUD) with respect to the rectal wall volume parameter. Radiother Oncol 2004; 73(2):209-218.

         (43)                            IF: 4.285               Sectie(s): IX
Seppenwoolde Y; De Jaeger K; Boersma LJ; Belderbos JSA; Lebesque JV. Regional differences in lung radiosensitivity after radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004; 60(3):748-758.

         (44)                            IF: 4.285               Sectie(s): IX
Seppenwoolde Y; De Jaeger K; Lebesque JV. (Lung V20 measurements ) Response to Drs. Garces and Miller [correspondence]. Int J Radiat Oncol Biol Phys 2004; 58:1636-1637.

         (45)                            IF: 4.285               Sectie(s): IX
Smitsmans MHP; Wolthaus JW; Artignan X; De Bois J; Jaffray DA; Lebesque JV; Van Herk M. Automatic localization of the prostate for on-line or off-line image-guided radiotherapy. Int J Radiat Oncol Biol Phys 2004; 60(2):623-635.

         (46)                            IF: 2.305               Sectie(s): IX
Sonke JJ; Ploeger LS; Brand B; Smitsmans MHP; Van Herk M. Leaf trajectory verification during dynamic intensity modulated radiotherapy using an amorphous silicon flat panel imager. Med Phys 2004; 31(2):389-395.

         (47)                            IF: 4.285               Sectie(s): IX
Steenbakkers RJ; Duppen JC; Betgen A; Lotz HT; Remeijer P; Fitton I; Nowak PJ; Van Herk M; Rasch CR. Impact of knee support and shape of tabletop on rectum and prostate position. Int J Radiat Oncol Biol Phys 2004; 60(5):1364-1372.

         (48)                            IF: 0.809               Sectie(s): IX, II
Tytgat GNJ; Bartelink H; Bernards R; Giaccone G; Van Lanschot JJB; Offerhaus GJA; Peters GJ. Cancer of the esophagus and gastric cardia: recent advances. Dis Esophagus 2004; 17(1):10-26.

         (49)                            IF: geen                Sectie(s): IX
Uitterhoeve ALJ; Belderbos JSA. M03IVC (CKTO 2003-04). Ned Tijdschr Oncol 2004; 1(4):157-158.

         (50)                            IF: 4.017               Sectie(s): XI, XIII, X, IX, BM
Van den Broek GB; Rasch CR; Pameijer FA; Peter E; Van den Brekel MWM; Tan IB; Schornagel JH; De Bois JA; Zijp LJ; Balm AJM. Pretreatment probability model for predicting outcome after intraarterial chemoradiation for advanced head and neck carcinoma. Cancer 2004; 101:1809-1817.

         (51)                                                    Sectie(s): III, IX
Van der Luit AH; Verheij M; Van Blitterswijk WJ. Raft lipid metabolism in relation to alkyl-lysophospholipid-induced apoptosis. In: Mattson MP, editor. Membrane microdomain signaling lipid rafts in biology and medicine. Totowa, NJ, USA: Humana Press, 2004: 91-112.

         (52)                            IF: 3.604               Sectie(s): IX
Van Herk M. Errors and margins in radiotherapy. Semin Radiat Oncol 2004; 14(1):52-64.

         (53)                            IF: 3.894               Sectie(s): III, IX
Veldman RJ; Zerp S; Van Blitterswijk WJ; Verheij M. N-hexanoyl-sphingomyelin potentiates in vitro doxorubicin cytotoxicity by enhancing its cellular influx. Br J Cancer 2004; 90(4):917-925.

         (54)                            IF: geen                Sectie(s): IX
Verheij M; Jansen EPM. Radiochemotherapie bij de behandeling van solide tumoren. Ned Tijdschr Oncol 2004; 1(1):16-20.

         (55)                            IF: 3.574               Sectie(s): XI, X, IX, BM
Verwaal VJ; Boot H; Aleman BMP; Van Tinteren H; Zoetmulder FAN. Recurrences after Peritoneal Carcinomatosis of Colorectal Origin Treated by Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy: Location, Treatment, and Outcome. Ann Surg Oncol 2004; 11(4):375-379.

         (56)                            IF: 13.844             Sectie(s): IX
Wallner P; Arthur D; Bartelink H; Connolly J; Edmundson G; Giuliano A; Goldstein N; Hevezi J; Julian T; Kuske R; Lichter A; McCormick B; Orecchia R; Pierce L; Powell S; Solin L; Vicini F; Whelan T; Wong J; Coleman CN. Workshop on partial breast irradiation: state of the art and the science, Bethesda, MD, December 8-10, 2002. J Natl Cancer Inst 2004; 96(3):175-184.

         (57)                            IF: 2.305               Sectie(s): IX
Witte MG; Van der Geer J; Schneider C; Lebesque JV; Van Herk M. The effects of target size and tissue density on the minimum margin required for random errors. Med Phys 2004; 31(11):3068-3079.

se-X=med.oncol.          (80)

           (1)                            IF: 1.805               Sectie(s): XI, X, IX, XIII
Balm AJM; Rasch CRN; Schornagel JH; Hilgers FJM; Keus RB; Schultze-Kool L; Ackerstaff AH; Busschers W; Tan IB. High-dose superselective intra-arterial cisplatin and concomitant radiation (RADPLAT) for advanced head and neck cancer. Head Neck 2004; 26(6):485-493.

           (2)                            IF: 2.272               Sectie(s): XIII, X
Bardelmeijer HA; Ouwehand M; Beijnen JH; Schellens JHM; Van Tellingen O. Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice. Invest New Drugs 2004; 22(3):219-229.

           (3)                            IF: 6.830               Sectie(s): X
Beijnen JH; Schellens JHM. Drug interactions in oncology [review]. Lancet Oncol 2004; 5(8):489-496.

           (4)                                                    Sectie(s): X
Beijnen JH, Schellens JHM. Geneesmiddeleninteracties met oncolytica. 2004 [Dissertation].

           (5)                            IF: 2.789               Sectie(s): X
Beumer JH; Rosing H; Hillebrand MJX; Nan-Offeringa LGAH; Foley K; Yule SM; Heck AJR; Schellens JHM; Beijnen JH. Quantitative determination of the novel anticancer drug E7070 (indisulam) and its metabolite (1,4-benzenedisulphonamide) in human plasma, urine and faeces by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom 2004; 18(23):2839-2848.

           (6)                            IF: geen                Sectie(s): X
Boogerd W. De rol van intrathecale chemotherapie bij de behandeling van leptomeningeale metastasen van solide tumoren. Ned Tijdschr Oncol 2004; 1:164-170.

           (7)                            IF: 3.694               Sectie(s): X, XII, IX
Boogerd W; Van den Bent MJ; Koehler PJ; Heimans JJ; Van der Sande JJ; Aaronson NK; Hart AAM; Benraadt J; Vecht ChJ. The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study. Eur J Cancer 2004; 40:2726-2733.

           (8)                            IF: geen                Sectie(s): X
Bouma M; Nuijen B; Challa EE; Sava G; Flaibani A; Bult A; Beijnen JH. Stability and compatibility of the investigational antimetastatic ruthenium complex NAMI-A in infusion systems and its hemolytic potential. J Oncol Pharm Practice 2004; 10:7-15.

           (9)                            IF: geen                Sectie(s): X
Bouma M; Nuijen B; Rice JR; Bult A; Beijnen JH. AP-5280: een polymeergekoppeld platinabevattend cytostaticum. Pharm Weekbl 2004; 139:996-999.

         (10)                            IF: geen                Sectie(s): X, XIII
Bouwman K; Gast MCW; Bonfrer JMG; Schellens JHM; Beijnen JH. Proteomics in de oncologie. Pharm Weekbl 2004; 139:879-884.

         (11)                            IF: 2.272               Sectie(s): X
Brandon EFA; Sparidans RW; Meijerman I; Manzanares I; Beijnen JH; Schellens JHM. In vitro characterization of the biotransformation of thiocoraline, a novel marine anti-cancer drug. Invest New Drugs 2004; 22(3):241-251.

         (12)                            IF: 8.649               Sectie(s): VIII, V, XIII, X
Breedveld P; Zelcer N; Pluim D; Sonmezer O; Tibben MM; Beijnen JH; Schinkel AH; Van Tellingen O; Borst P; Schellens JHM. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res 2004; 64(16):5804-5811.

         (13)                            IF: geen                Sectie(s): X
Bruininx EPM; Liu SY; Verheij MBM; Beijnen JH. Intoxicaties met organofosfaten. Twijfel over oximen belet toepassing niet. Pharm Weekbl 2004; 139:1245-1250.

         (14)                            IF: geen                Sectie(s): X
Burgers JA; Baas P; Van Zandwijk N. [Bronchoscopy: new diagnostic and therapeutic applications, new indications]
Bronchoscopie: nieuwe diagnostische en therapeutische technieken, nieuwe indicaties. Ned Tijdschr Geneeskd 2004; 148(26):1280-1285.

         (15)                            IF: 1.798               Sectie(s): X
Burgers JA; Damhuis RAM. Prognostic factors in malignant mesothelioma. Lung Cancer 2004; 45 Suppl 1:S49-S54.

         (16)                            IF: 3.894               Sectie(s): X
Calvet L; Santos A; Valent A; Terrier-Lacombe MJ; Opolon P; Merlin JL; Aubert G; Morizet J; Schellens JHM; Benard J; Vassal G. No topoisomerase I alteration in a neuroblastoma model with in vivo acquired resistance to irinotecan. Br J Cancer 2004; 91:1205-1212.

         (17)                            IF: 12.718             Sectie(s): X
De Jong AE; Morreau H; Van Puijenbroek M; Eilers PHC; Wijnen J; Nagengast FM; Griffioen G; Cats A; Menko FH; Kleibeuker JH; Vasen HFA. The role of mismatch repair gene defects in the development of adenomas in patients with HNPCC. Gastroenterology 2004; 126(1):42-48.

         (18)                            IF: 6.511               Sectie(s): X
De Jonge ME; Van den Bongard HJGD; Huitema ADR; Mathot RAA; Rosing H; Baas P; Van Zandwijk N; Beijnen JH; Schellens JHM. Bayesian pharmacokinetically guided dosing of paclitaxel in patients with non-small cell lung cancer. Clin Cancer Res 2004; 10(7):2237-2244.

         (19)                            IF: 2.875               Sectie(s): X
De Jonge ME; Van Dam SM; Hillebrand MJX; Rosing H; Huitema ADR; Rodenhuis S; Beijnen JH. Simultaneous quantification of cyclophosphamide, 4-hydroxycyclophosphamide, N,N',N"-triethylenethiophosphoramide (thiotepa) and N,N',N"-triethylenephosphoramide (tepa) in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. J Mass Spectrom 2004; 39(3):262-271.

         (20)                            IF: 1.625               Sectie(s): X
De Jonge ME; Huitema AD; Rodenhuis S; Beijnen JH. Integrated Population Pharmacokinetic Model of both cyclophosphamide and thiotepa suggesting a mutual drug-drug interaction. J Pharmacokinet Pharmacodyn 2004; 31(2):135-156.

         (21)                                                    Sectie(s): X
De Jonge ME. Pharmacokinetically guided dosing of (high-dose) chemotherapeutic agents - Farmacokinetisch gestuurde toediening van (hooggedoseerde) chemotherapie. Utrecht: Utrecht University, 2004 [Dissertation].

         (22)                            IF: 0.619               Sectie(s): X, XI, XIII
De Vos tot Nederveen Cappel RJ; Van Hillegersberg R; Rodenhuis S; Peterse JL; Van Coevorden F. Downstaging of an advanced gastrointestinal stromal tumor by neoadjuvant imatinib. Dig Surg 2004; 21(1):77-79.

         (23)                            IF: 4.375               Sectie(s): X
De Vos tot Nederveen Cappel WH; Meulenbeld HJ; Kleibeuker JH; Nagengast FM; Menko FH; Griffioen G; Cats A; Morreau H; Gelderblom H; Vasen HFA. Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer. Int J Cancer 2004; 109(3):468-471.

         (24)                            IF: 1.539               Sectie(s): X
Den Brok MWJ; Van der Schoot SC; Nuijen B; Hillebrand MJX; Beijnen JH. 2-Hydroxypropyl-beta-cyclodextrin extracts 2-phenylphenol from silicone tubing. Int J Pharm 2004; 278(2):303-309.

         (25)                            IF: geen                Sectie(s): X
Denissen JFPM; Tanwir MK; Woi A Sioe WJ; Schellens JHM. Let op vocht en interacties
18. Pharm Weekbl 2004; 139:1358-1362.

         (26)                            IF: 6.511               Sectie(s): VIII, XIII, X, BM
Faneyte IF; Peterse JL; Van Tinteren H; Pronk C; De Vries EGE; Rodenhuis S; Van de Vijver MJ. Predicting early failure after adjuvant chemotherapy in high-risk breast cancer patients with extensive lymph node involvement. Clin Cancer Res 2004; 10(13):4457-4463.

         (27)                            IF: 6.511               Sectie(s): X
Fracasso PM; Goldstein LJ; De Alwis DP; Rader JS; Arquette MA; Goodner SA; Wright LP; Fears CL; Gazak RJ; Andre VAM; Burgess MF; Slapak CA; Schellens JHM. Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies. Clin Cancer Res 2004; 10(21):7220-7228.

         (28)                            IF: 3.625               Sectie(s): X
Gatzemeier U; Groth G; Butts C; Van Zandwijk N; Shepherd F; Ardizzoni A; Barton C; Ghahramani P; Hirsh V. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol 2004; 15(1):19-27.

         (29)                            IF: 3.625               Sectie(s): X
Gridelli C; Ardizzoni A; Le Chevalier T; Manegold C; Perrone F; Thatcher N; Van Zandwijk N; Di Maio M; Martelli O; De Marinis F. Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. Ann Oncol 2004; 15(3):419-426.

         (30)                            IF: 3.625               Sectie(s): X, BM
Haringhuizen A; Van Tinteren H; Vaessen HFR; Baas P; Van Zandwijk N. Gefitinib as a last treatment option for non-small-cell lung cancer: durable disease control in a subset of patients. Ann Oncol 2004; 15(5):786-792.

         (31)                            IF: 18.316             Sectie(s): IX, X
Homs MY; Steyerberg EW; Eijkenboom WMH; Tilanus HW; Stalpers LJ; Bartelsman JF; Van Lanschot JJB; Wijrdeman HK; Mulder CJ; Reinders JG; Boot H; Aleman BMP; Kuipers EJ; Siersema PD. Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial. Lancet 2004; 364(9444):1497-1504.

         (32)                            IF: geen                Sectie(s): IX, X, XI
Jansen EPM; Boot H; Cats A; Van Coevorden F; Zoetmulder FAN; Verheij M. [New insights in the adjuvant treatment of gastric cancer]
Nieuwe inzichten in de adjuvante behandeling van het maagcarcinoom. Ned Tijdschr Geneeskd 2004; 148(51):2529-2534.

         (33)                            IF: 0.456               Sectie(s): X
Joerger M; Schellens JHM; Beijnen JH. Therapeutic drug monitoring of non-anticancer drugs in cancer patients. Methods Find Exp Clin Pharmacol 2004; 26(7):531-545.

         (34)                            IF: 2.870               Sectie(s): XIII, IX,X
Kartachova M; Haas RLM; Valdés Olmos RA; Hoebers FJP; Van Zandwijk N; Verheij M. In vivo imaging of apoptosis by (99m)Tc-Annexin V scintigraphy: visual analysis in relation to treatment response. Radiother Oncol 2004; 72(3):333-339.

         (35)                            IF: 3.694               Sectie(s): XIII, IX, X
Kemper EM; Verheij M; Boogerd W; Beijnen JH; Van Tellingen O. Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein. Eur J Cancer 2004; 40(8):1269-1274.

         (36)                            IF: 2.046               Sectie(s): XIII, X
Kemper EM; Cleypool C; Boogerd W; Beijnen JH; Van Tellingen O. The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice. Cancer Chemother Pharmacol 2004; 53(2):173-178.

         (37)                            IF: 2.969               Sectie(s): XIII., X
Kemper EM; Boogerd W; Thuis I; Beijnen JH; Van Tellingen O. Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours? [review]. Cancer Treat Rev 2004; 30(5):415-423.

         (38)                            IF: 3.894               Sectie(s): X
Kerbusch T; Groenewegen G; Mathot RAA; Herben VMM; Ten Bokkel Huinink WW; Swart M; Ambaum B; Rosing H; Jansen S; Voest EE; Beijnen JH; Schellens JHM. Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks. Br J Cancer 2004; 90(12):2268-2277.

         (39)                            IF: geen                Sectie(s): X, XI, XIII, IX
Kerst JM; Van Coevorden F; Peterse J; Haas RLM; Linn SC. Jongvolwassenen met Ewing-sarcomen
[Young adults with Ewing's sarcoma]. Ned Tijdschr Geneeskd 2004; 148(27):1355-1358.

         (40)                            IF: geen                Sectie(s): X
Kukreja J; Jaklitsch MT; Wiener DC; Sugarbaker DJ; Burgers S; Baas P. Malignant pleural mesothelioma: overview of the North American and European experience. Thorac Surg Clin 2004; 14(4):435-445.

         (41)                            IF: 12.427             Sectie(s): X
Kuppens IELM; Boot H; Beijnen JH; Schellens JHM; Labadie J. Capecitabine induces severe angina-like chest pain [letter]. Ann Intern Med 2004; 140(6):494-495.

         (42)                            IF: geen                Sectie(s): X
Kuppens IELM; Beijnen J; Schellens JHM. Topoisomerase I inhibitors in the treatment of gastrointestinal cancer: from intravenous to oral administration. Clin Colorectal Cancer 2004; 4(3):163-180.

         (43)                                                    Sectie(s): X
Kuppens IELM. Clinical and pharmacological studies with oral anti-cancer drugs - Klinische en farmacologische studies met orale chemotherapeutica. Utrecht: Utrecht University, 2004 [Dissertation].

         (44)                                                    Sectie(s): X
Mallo HA; Batchelor DM; Haanen JBAG. Biotherapie/immunotherapie. In: Klaren AD, Van der Meer CA, editors. Oncologie: handboek voor verpleegkundigen en andere hulpverleners. Houten/Antwerpen: Bohn Stafleu Van Loghum, 2004: 223-263.

         (45)                            IF: 2.140               Sectie(s): X
Meijer JW; Mulder CJ; Goerres MG; Boot H; Schweizer JJ. Coeliac disease and (extra)intestinal T-cell lymphomas: definition, diagnosis and treatment. Scand J Gastroenterol Suppl 2004;(241):78-84.

         (46)                            IF: 3.694               Sectie(s): X
Moser EC; Noordijk EM; Van Glabbeke M; Teodorovic I; De Wolf-Peeters C; Carde P; Baars JW; Tirelli U; Raemaekers JMM; Kluin-Nelemans JC. Long-term efficacy of the CHVmP/BV regimen used for aggressive non-Hodgkin's lymphoma in three randomised EORTC trials. Eur J Cancer 2004; 40(4):474-480.

         (47)                            IF: 6.511               Sectie(s): X
Peters GJ; Noordhuis P; Van Groeningen CJ; Giaccone G; Holwerda U; Voorn D; Schrijvers A; Schornagel JH; Beijnen JH; Fumoleau P; Schellens JHM. The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors. Clin Cancer Res 2004; 10(12 Pt 1):4072-4076.

         (48)                            IF: 2.046               Sectie(s): VIII, X
Pluim D; Van Waardenburg RCAM; Beijnen JH; Schellens JHM. Cytotoxicity of the organic ruthenium anticancer drug Nami-A is correlated with DNA binding in four different human tumor cell lines. Cancer Chemother Pharmacol 2004; 54(1):71-78.

         (49)                            IF: 6.511               Sectie(s): VIII, X
Rademaker-Lakhai JM; Van den Bongard D; Pluim D; Beijnen JH; Schellens JHM. A phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent. Clin Cancer Res 2004; 10(11):3717-3727.

         (50)                            IF: 6.511               Sectie(s): VIII, X
Rademaker-Lakhai JM; Terret C; Howell SB; Baud CM; De Boer RF; Pluim D; Beijnen JH; Schellens JHM; Droz JP. A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors. Clin Cancer Res 2004; 10(10):3386-3395.

         (51)                                                    Sectie(s): X
Rademaker-Lakhai JM. Clinical pharmacology of metal-based and marine-derived anticancer agents - Klinische farmacologie van op metaal-gebaseerde en uit de zee afkomstige antikanker middelen. Utrecht: Utrecht University, 2004 [Dissertation].

         (52)                            IF: geen                Sectie(s): X
Rodriguez E; Baas P; Friedberg JS. Innovative therapies: photodynamic therapy. Thorac Surg Clin 2004; 14(4):557-566.

         (53)                            IF: 3.694               Sectie(s): X
Rothbarth J; Tollenaar RAEM; Schellens JHM; Nortier JWR; Schultze Kool LJ; Kuppen PJK; Mulder GJ; Van de Velde CJH. Isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: recent trends and perspectives. Eur J Cancer 2004; 40(12):1812-1824.

         (54)                            IF: 4.246               Sectie(s): VIII, X
Sankatsing SU; Beijnen JH; Schinkel AH; Lange JMA; Prins JM. P glycoprotein in human immunodeficiency virus type 1 infection and therapy. Antimicrob Agents Chemother 2004; 48(4):1073-1081.

         (55)                            IF: 3.894               Sectie(s): X
Schoemaker NE; Kuppens IELM; Moiseyenko V; Glimelius B; Kjaer M; Starkhammer H; Richel DJ; Smaaland R; Bertelsen K; Poulsen JP; Voznyi E; Norum J; Fennelly D; Tveit KM; Garin A; Gruia G; Mourier A; Sibaud D; Lefebvre P; Beijnen JH; Schellens JHM; Ten Bokkel Huinink WW. A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer. Br J Cancer 2004; 91:1434-1441.

         (56)                            IF: 2.041               Sectie(s): X
Schouwink H; Baas P. Foscan-mediated photodynamic therapy and operation for malignant pleural mesothelioma [letter]. Ann Thorac Surg 2004; 78(1):388.

         (57)                                                    Sectie(s): X
Schrama JG. Patient selection for high-dose chemotherapy in stage II and IV breast cancer. Amsterdam: University of Amsterdam, 2004 [Dissertation].

         (58)                            IF: 1.269               Sectie(s): X
Sparidans RW; Schellens JHM; Lopez-Lazaro L; Jimeno JM; Beijnen JH. Liquid chromatographic assay for the cyclic depsipeptide aplidine, a new marine antitumor drug, in whole blood using derivatization with trans-4'-hydrazino-2-stilbazole. Biomed Chromatogr 2004; 18(1):16-20.

         (59)                            IF: 2.875               Sectie(s): X
Stokvis E; Rosing H; Lopez-Lazaro L; Beijnen JH. Simple and sensitive liquid chromatographic quantitative analysis of the novel marine anticancer drug Yondelis (ET-743, trabectedin) in human plasma using column switching and tandem mass spectrometric detection. J Mass Spectrom 2004; 39(4):431-436.

         (60)                            IF: 1.269               Sectie(s): X
Stokvis E; Rosing H; Lopez-Lazaro L; Schellens JHM; Beijnen JH. A more sensitive MS detector does not obviously lead to a more sensitive assay: experiences with ES-285. Biomed Chromatogr 2004; 18(6):403-407.

         (61)                            IF: 1.269               Sectie(s): X
Stokvis E; Rosing H; Lopez-Lazaro L; Schellens JHM; Beijnen JH. Switching from an analogous to a stable isotopically labeled internal standard for the LC-MS/MS quantitation of the novel anticancer drug Kahalalide F significantly improves assay performance. Biomed Chromatogr 2004; 18(6):400-402.

         (62)                            IF: 2.789               Sectie(s): X
Stokvis E; Nan-Offeringa LGAH; Ouwehand M; Tibben MM; Rosing H; Schnaars Y; Grigat M; Romeis P; Schellens JHM; Beijnen JH. Quantitative analysis of D-24851, a novel anticancer agent, in human plasma and urine by liquid chromatography coupled with tandem mass spectrometry. Rapid Commun Mass Spectrom 2004; 18(13):1465-1471.

         (63)                            IF: 2.875               Sectie(s): X
Stokvis E; Rosing H; Crul M; Rieser MJ; Heck AJR; Schellens JHM; Beijnen JH. Quantitative analysis of the novel anticancer drug ABT-518, a matrix metalloproteinase inhibitor, plus the screening of six metabolites in human plasma using high-performance liquid chromatography coupled with electrospray tandem mass spectrometry. J Mass Spectrom 2004; 39(3):277-288.

         (64)                            IF: 2.875               Sectie(s): X
Stokvis E; Rosing H; Causon RC; Schellens JHM; Beijnen JH. Quantitative analysis of the P-glycoprotein inhibitor Elacridar (GF120918) in human and dog plasma using liquid chromatography with tandem mass spectrometric detection. J Mass Spectrom 2004; 39(10):1122-1130.

         (65)                            IF: 2.875               Sectie(s): X, XIII
Stokvis E; Ouwehand M; Nan LG; Kemper EM; Van Tellingen O; Rosing H; Beijnen JH. A simple and sensitive assay for the quantitative analysis of paclitaxel in human and mouse plasma and brain tumor tissue using coupled liquid chromatography and tandem mass spectrometry. J Mass Spectrom 2004; 39(12):1506-1512.

         (66)                            IF: 2.844               Sectie(s): X
Taal BG; Visser O. Epidemiology of neuroendocrine tumours. Neuroendocrinology 2004; 80 Suppl 1:3-7.

         (67)                            IF: 3.625               Sectie(s): X
Ten Bokkel Huinink W; Lane SR; Ross GA. Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Ann Oncol 2004; 15(1):100-103.

         (68)                            IF: 2.174               Sectie(s): X, XIII
Van den Bongard HJGD; Kemper EM; Van Tellingen O; Rosing H; Mathot RAA; Schellens JHM; Beijnen JH. Development and validation of a method to determine the unbound paclitaxel fraction in human plasma. Anal Biochem 2004; 324(1):11-15.

         (69)                            IF: 2.272               Sectie(s): X
Van den Bongard HJGD; Sparidans RW; Critchley DJP; Beijnen JH; Schellens JHM. Pharmacokinetic drug-drug interaction of the novel anticancer agent E7070 and acenocoumarol. Invest New Drugs 2004; 22(2):151-158.

         (70)                            IF: 4.017               Sectie(s): XI, XIII, X, IX, BM
Van den Broek GB; Rasch CR; Pameijer FA; Peter E; Van den Brekel MWM; Tan IB; Schornagel JH; De Bois JA; Zijp LJ; Balm AJM. Pretreatment probability model for predicting outcome after intraarterial chemoradiation for advanced head and neck carcinoma. Cancer 2004; 101:1809-1817.

         (71)                            IF: 6.511               Sectie(s): IV, X, BM
Van Oijen M; Bins A; Elias S; Sein J; Weder P; De Gast G; Mallo H; Gallee M; Van Tinteren H; Schumacher T; Haanen J. On the role of melanoma-specific CD8+ T-cell immunity in disease progression of advanced-stage melanoma patients. Clin Cancer Res 2004; 10(14):4754-4760.

         (72)                            IF: 3.899               Sectie(s): XI, X
Van Ruth S; Mathot RA; Sparidans RW; Beijnen JH; Verwaal VJ; Zoetmulder FAN. Population pharmacokinetics and pharmacodynamics of mitomycin during intraoperative hyperthermic intraperitoneal chemotherapy. Clin Pharmacokinet 2004; 43(2):131-143.

         (73)                            IF: 3.201               Sectie(s): VIII, X
Van Waardenburg RCAM; De Jong LA; Van Delft F; Van Eijndhoven MAJ; Bohlander M; Bjornsti MA; Brouwer J; Schellens JHM. Homologous recombination is a highly conserved determinant of the synergistic cytotoxicity between cisplatin and DNA topoisomerase I poisons. Mol Cancer Ther 2004; 3(4):393-402.

         (74)                            IF: 6.482               Sectie(s): VIII, X
Van Waardenburg RCAM; De Jong LA; Van Eijndhoven MAJ; Verseyden C; Pluim D; Jansen LE; Bjornsti MA; Schellens JHM. Platinated DNA adducts enhance poisoning of DNA topoisomerase I by camptothecin. J Biol Chem 2004; 279:54502-54509.

         (75)                            IF: 8.649               Sectie(s): IV, X
Verra NCV; Jorritsma A; Weijer K; Ruizendaal JJ; Voordouw A; Weder P; Hooijberg E; Schumacher TNM; Haanen JBAG; Spits H; Luiten RM. Human telomerase reverse transcriptase-transduced human cytotoxic T cells suppress the growth of human melanoma in immunodeficient mice. Cancer Res 2004; 64(6):2153-2161.

         (76)                            IF: 3.574               Sectie(s): XI, X, IX, BM
Verwaal VJ; Boot H; Aleman BMP; Van Tinteren H; Zoetmulder FAN. Recurrences after Peritoneal Carcinomatosis of Colorectal Origin Treated by Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy: Location, Treatment, and Outcome. Ann Surg Oncol 2004; 11(4):375-379.

         (77)                            IF: 2.046               Sectie(s): VIII, X
Zamboni WC; Gervais AC; Egorin MJ; Schellens JHM; Zuhowski EG; Pluim D; Joseph E; Hamburger DR; Working PK; Colbern G; Tonda ME; Potter DM; Eiseman JL. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma. Cancer Chemother Pharmacol 2004; 53(4):329-336.

         (78)                            IF: 5.538               Sectie(s): X, XIII, BM
Zuetenhorst JM; Korse CM; Bonfrer JMG; Peter E; Lamers CBHW; Taal BG. Daily cyclic changes in the urinary excretion of 5-hydroxyindoleacetic Acid in patients with carcinoid tumors. Clin Chem 2004; 50(9):1634-1639.

         (79)                            IF: 3.894               Sectie(s): X, XIII
Zuetenhorst JM; Korse CM; Bonfrer JMG; Bakker RH; Taal BG. Role of natriuretic peptides in the diagnosis and treatment of patients with carcinoid heart disease. Br J Cancer 2004; 90(11):2073-2079.

         (80)                            IF: 8.894               Sectie(s): X, XIII
Zuetenhorst JM; Valdés Olmos RA; Muller M; Hoefnagel CA; Taal BG. Interferon and meta-iodobenzylguanidin combinations in the treatment of metastatic carcinoid tumours. Endocr Relat Cancer 2004; 11(3):553-561.

se-XI=surg.oncol.        (98)

           (1)                            IF: 3.894               Sectie(s): XI
Albrecht W; Van Poppel H; Horenblas S; Mickisch G; Horwich A; Serretta V; Casetta G; Marechal JM; Jones WG; Kalman S; Sylvester R. Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer. Br J Cancer 2004; 90(1):100-105.

           (2)                            IF: 1.865               Sectie(s): XI, BM
Bakx R; Van Tinteren H; Van Lanschot JJB; Zoetmulder FAN. Surgical treatment of locally recurrent rectal cancer. Eur J Surg Oncol 2004; 30(8):857-863.

           (3)                            IF: 2.071               Sectie(s): XI
Bakx R; Van Lanschot JJB; Zoetmulder FAN. Sacral resection in cancer surgery: surgical technique and experience in 26 procedures. J Am Coll Surg 2004; 198(5):846-851.

           (4)                            IF: 1.991               Sectie(s): XI
Bakx R; Van Lanschot JJB; Zoetmulder FAN. Inferiorly based rectus abdominis myocutaneous flaps in surgical oncology: Indications, technique, and experience in 37 patients. J Surg Oncol 2004; 85(2):93-97.

           (5)                            IF: 1.805               Sectie(s): XI, X, IX, XIII
Balm AJM; Rasch CRN; Schornagel JH; Hilgers FJM; Keus RB; Schultze-Kool L; Ackerstaff AH; Busschers W; Tan IB. High-dose superselective intra-arterial cisplatin and concomitant radiation (RADPLAT) for advanced head and neck cancer. Head Neck 2004; 26(6):485-493.

           (6)                            IF: 2.183               Sectie(s): XI, XIII
De Bree E; Zoetmulder FAN; Keus RB; Peterse HL; Van Coevorden F. Incidence and treatment of recurrent plantar fibromatosis by surgery and postoperative radiotherapy. Am J Surg 2004; 187(1):33-38.

           (7)                            IF: 1.991               Sectie(s): XI
De Bree E; Koops W; Kroger R; Van Ruth S; Witkamp AJ; Zoetmulder FAN. Peritoneal carcinomatosis from colorectal or appendiceal origin: correlation of preoperative CT with intraoperative findings and evaluation of interobserver agreement. J Surg Oncol 2004; 86(2):64-73.

           (8)                            IF: 4.899               Sectie(s): XI, XIII
De Jong M; Valkema R; Van Gameren A; Van Boven H; Bex A; Van de Weyer EP; Burggraaf JD; Korner M; Reubi JC; Krenning EP. Inhomogeneous localization of radioactivity in the human kidney after injection of [(111)In-DTPA]octreotide. J Nucl Med 2004; 45(7):1168-1171.

           (9)                            IF: 0.619               Sectie(s): X, XI, XIII
De Vos tot Nederveen Cappel RJ; Van Hillegersberg R; Rodenhuis S; Peterse JL; Van Coevorden F. Downstaging of an advanced gastrointestinal stromal tumor by neoadjuvant imatinib. Dig Surg 2004; 21(1):77-79.

         (10)                                                    Sectie(s): XI
De Vries JDH; Nieweg OE; Uren RF. Positron emission tomography. In: Thompson JF, Morton DL, Kroon BBR, editors. Textbook of melanoma. London: Martin Dunitz, 2004: 477-481.

         (11)                            IF: 4.285               Sectie(s): IX, XI, XIII
Eisbruch A; Schwartz M; Rasch C; Vineberg K; Damen E; Van As CJ; Marsh R; Pameijer FA; Balm AJM. Dysphagia and aspiration after chemoradiotherapy for head-and-neck cancer: which anatomic structures are affected and can they be spared by IMRT? Int J Radiat Oncol Biol Phys 2004; 60(5):1425-1439.

         (12)                                                    Sectie(s): XI
Essner R; Thompson JF; Nieweg OE. The sentinel lymph node procedure: identification with blue dye and a gamma probe. In: Thompson JF, Morton DL, Kroon BBR, editors. Textbook of melanoma. London: Martin Dunitz, 2004: 328-338.

         (13)                                                    Sectie(s): XI
Estourgie SH. Clinical relevance and refinement of the sentinel node procedure uin breast cancer and melanoma. Universiteit van Amsterdam, 2004 [Dissertation].

         (14)                            IF: 5.937               Sectie(s): XI, XIII
Estourgie SH; Nieweg OE; Valdés Olmos RA; Rutgers EJT; Kroon BBR. Internal mammary chain drainage of breast cancer: reply. Ann Surg 2004; 240(3):558.

         (15)                            IF: 5.937               Sectie(s): XI, XIII
Estourgie SH; Nieweg OE; Valdés Olmos RA; Rutgers EJT; Kroon BBR. Lymphatic drainage patterns from the breast. Ann Surg 2004; 239(2):232-237.

         (16)                            IF: 3.772               Sectie(s): XI
Estourgie SH; Nieweg OE; Kroon BBR. High incidence of in-transit metastases after sentinel node biopsy in patients with melanoma. Br J Surg 2004; 91(10):1370.

         (17)                            IF: 1.865               Sectie(s): XI
Estourgie SH; Nieweg OE; Kroon BBR. The sentinel node procedure in patients with melanoma [editorial]. Eur J Surg Oncol 2004; 30(7):713-714.

         (18)                            IF: 4.017               Sectie(s): XI
Fossa SD; Mickisch GHJ; De Mulder PHM; Horenblas S; Van Oosterom AT; Van Poppel H; Fey M; Croles JJ; De Prijck L; Van Glabbeke M. Interferon-alpha-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma. Cancer 2004; 101(3):533-540.

         (19)                            IF: 1.230               Sectie(s): XI, XIII
Gallegos Hernandez JF; Tanis PJ; Deurloo EE; Nieweg OE; Rutgers EJT; Kroon BBR; Valdés Olmos RA. Radio-guided surgery improves outcome of therapeutic excision in non-palpable invasive breast cancer. Nucl Med Commun 2004; 25(3):227-232.

         (20)                            IF: geen                Sectie(s): XI
Geurts TW; Van den Akker HP; Balm AJM. Cervicale ranula. Ned Tijdschr Geneeskd 2004; 148(8):388-391.

         (21)                            IF: 0.791               Sectie(s): XI
Hage JJ; Woerdeman LAE. Lower limb necrosis after use of the anterolateral thigh free flap: is preoperative angiography indicated? Ann Plast Surg 2004; 52(3):315-318.

         (22)                                                    Sectie(s): XI
Haubrich H; Van Beurden M. Gynaecologische tumoren. In: Klaren AD, Van der Meer CA, editors. Oncologie: handboek voor verpleegkundigen en andere hulpverleners. Houten/Antwerpen: Bohn Stafleu Van Loghum, 2004: 461-506.

         (23)                            IF: 4.375               Sectie(s): XI
Hopper C; Kubler A; Lewis H; Tan IB; Putnam G. mTHPC-mediated photodynamic therapy for early oral squamous cell carcinoma. Int J Cancer 2004; 111(1):138-146.

         (24)                            IF: geen                Sectie(s): XI
Huitink JM; Schutte PFE. Intercollegiaal consult en second opinion in de anesthesiologie. Ned Tijdschr Anesth 2004; 4:118-124.

         (25)                            IF: 0.715               Sectie(s): XI
Jairath D; Hage JJ. Deep circumflex iliac artery (DCIA) free flap without DCIA: report of a unique case. J Reconstr Microsurg 2004; 20(7):519-521.

         (26)                            IF: geen                Sectie(s): IX, X, XI
Jansen EPM; Boot H; Cats A; Van Coevorden F; Zoetmulder FAN; Verheij M. [New insights in the adjuvant treatment of gastric cancer]
Nieuwe inzichten in de adjuvante behandeling van het maagcarcinoom. Ned Tijdschr Geneeskd 2004; 148(51):2529-2534.

         (27)                            IF: 2.870               Sectie(s): VIII, IX, XI
Janssen HL; Hoebers FJP; Sprong D; Goethals L; Williams KJ; Stratford IJ; Haustermans KM; Balm AJM; Begg AC. Differentiation-associated staining with anti-pimonidazole antibodies in head and neck tumors. Radiother Oncol 2004; 70(1):91-97.

         (28)                            IF: 3.694               Sectie(s): XI
Jassem J; Buchanan M; Janicke F; Baum M; Cataliotti L; Kyriakides S; Piccart M; Rutgers EJT; Costa A. The Hamburg statement: the partnership driving the European agenda on breast cancer. Eur J Cancer 2004; 40(12):1810-1811.

         (29)                            IF: 1.969               Sectie(s): XI, XIII
Kaas R; Kroger R; Hendriks JHCL; Besnard APE; Koops W; Pameijer FA; Prevoo W; Loo CE; Muller SH. The significance of circumscribed malignant mammographic masses in the surveillance of BRCA 1/2 gene mutation carriers. Eur Radiol 2004; 14(9):1647-1653.

         (30)                            IF: geen                Sectie(s): X, XI, XIII, IX
Kerst JM; Van Coevorden F; Peterse J; Haas RLM; Linn SC. Jongvolwassenen met Ewing-sarcomen
[Young adults with Ewing's sarcoma]. Ned Tijdschr Geneeskd 2004; 148(27):1355-1358.

         (31)                                                    Sectie(s): XI
Klaase JM; Kroon BBR. Gastrointestinal and other intraabdominal melanoma metastases. In: Thompson JF, Morton DL, Kroon BBR, editors. Textbook of melanoma. London: Martin Dunitz, 2004: 514-518.

         (32)                            IF: 34.833             Sectie(s): XI, XIII
Kriege M; Brekelmans CTM; Boetes C; Besnard PE; Zonderland HM; Obdeijn IM; Manoliu RA; Kok Th; Peterse H; Tilanus-Linthorst MMA; Muller SH; Meijer S; Oosterwijk JC; Beex LVAM; Tollenaar RAEM; De Koning HJ; Rutgers EJT; Klijn JGM; for the Magnetic Resonance Imaging Screening Study Group. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004; 351(5):427-437.

         (33)                            IF: 1.991               Sectie(s): XI
Kroon BK; Horenblas S; Nieweg OE. Re: Gipponi M, Solari N, Di Somma FC, et al.: New fields of application of the sentinel lymph node biopsy in the pathologic staging of solid neoplasms: review of literature and surgical perspectives. J Surg Oncol 2004: 85:171-179 [letter]. J Surg Oncol 2004; 87(2):107.

         (34)                            IF: 3.297               Sectie(s): XI, XIII
Kroon BK; Horenblas S; Estourgie SH; Lont AP; Valdés Olmos RA; Nieweg OE. How to avoid false-negative dynamic sentinel node procedures in penile carcinoma. J Urol 2004; 171(6 Pt 1):2191-2194.

         (35)                            IF: 1.991               Sectie(s): XI
Kroon BK; Horenblas S; Nieweg OE. Contemporary management of penile squamous cell carcinoma. J Surg Oncol 2004; 89(1):43-50.

         (36)                            IF: 2.183               Sectie(s): XI
Lohuis PJ; Klop WM; Tan IB; Van den Brekel MWM; Hilgers FJM; Balm AJM. Effectiveness of therapeutic (N1, N2) selective neck dissection (levels II to V) in patients with laryngeal and hypopharyngeal squamous cell carcinoma. Am J Surg 2004; 187(2):295-299.

         (37)                            IF: 3.297               Sectie(s): XI
Lont AP; Gallee MPW; Snijders P; Horenblas S. Sarcomatoid squamous cell carcinoma of the penis: a clinical and pathological study of 5 cases. J Urol 2004; 172(3):932-935.

         (38)                                                    Sectie(s): XI
McCarthy WH; Kroon BBR. Guidelines for the management of melanoma. In: Thompson JF, Morton DL, Kroon BBR, editors. Textbook of melanoma. London: Martin Dunitz, 2004: 672-679.

         (39)                            IF: geen                Sectie(s): XI, XIII
Meijnen P; Peterse JL; Nieweg OE; Rutgers EJT. [Detailed pathological examination of the sentinel lymph nodes in order to detect micrometastases: no clinical relevance in patients with breast cancer]
Intensieve bewerking van schildwachtklieren om micrometastasen te detecteren: geen klinische relevantie bij patienten met mammacarcinoom. Ned Tijdschr Geneeskd 2004; 148(49):2428-2432.

         (40)                            IF: 3.894               Sectie(s): XI
Molenaar S; Oort F; Sprangers M; Rutgers E; Luiten E; Mulder J; De Haes H. Predictors of patients' choices for breast-conserving therapy or mastectomy: a prospective study. Br J Cancer 2004; 90(11):2123-2130.

         (41)                            IF: 2.247               Sectie(s): XI
Naderi N; Nieuwenhuijzen JA; Bex A; Kooistra A; Horenblas S. Port site metastasis after laparoscopic nephro-ureterectomy for transitional cell carcinoma. Eur Urol 2004; 46(4):440-441.

         (42)                            IF: 1.642               Sectie(s): XI, IX, BM
Nieuwenhuijzen JA; Horenblas S; Meinhardt W; Van Tinteren H; Moonen LMF. Salvage cystectomy after failure of interstitial radiotherapy and external beam radiotherapy for bladder cancer. BJU Int 2004; 94(6):793-797.

         (43)                                                    Sectie(s): XI
Nieweg OE; Uren RF; Thompson JF. Sentinel lymph node biopsy: unresolved questions. In: Thompson JF, Morton DL, Kroon BBR, editors. Textbook of melanoma. London: Martin Dunitz, 2004: 373-378.

         (44)                            IF: 3.694               Sectie(s): XI, IX
Nieweg OE; Bartelink H. Implications of lymphatic mapping for staging and adjuvant treatment of patients with breast cancer. Eur J Cancer 2004; 40(2):179-181.

         (45)                            IF: geen                Sectie(s): XI
Nieweg OE; Estourgie SH; Valdés Olmos RA; Mooi WJ; Haanen JBAG; Kroon BBR. Sentinel node procedure bij het melanoom - meer vragen dan antwoorden. Ned Tijdschr Oncol 2004; 1(1):3-8.

         (46)                            IF: 1.991               Sectie(s): XI
Nieweg OE; Estourgie SH; Van Rijk MC; Kroon BBR. Rationale for superficial injection techniques in lymphatic mapping in breast cancer patients. J Surg Oncol 2004; 87(4):153-156.

         (47)                            IF: 1.991               Sectie(s): XI
Nieweg OE; Van Rijk MC; Tanis PJ; Estourgie SH. Commentary on Barranger et al., Contralateral axillary lymph node drainage in breast cancer: a case report: unusual lymph drainage pathways in patients with breast cancer [letter]. J Surg Oncol 2004; 87(2):105-106.

         (48)                            IF: 3.574               Sectie(s): XI
Nieweg OE; Estourgie SH. What is a sentinel node and what is a false-negative sentinel node? Ann Surg Oncol 2004; 11(3 Suppl):169S-173S.

         (49)                            IF: 1.991               Sectie(s): XI
Nieweg OE. Commentary (Omitting axillary lymph node dissection in sentinel node negative breast cancer patients is safe: A long term follow-up analysis) [letter]. J Surg Oncol 2004; 88(1):7.

         (50)                                                    Sectie(s): XI, XIII
Nieweg OE; Estourgie SH; Valdés Olmos RA. Lymphatic mapping and sentinel node biopsy. In: Ell PJ, Gambir SS, editors. Nuclear medicine in clinical diagnosis and treatment, Vol 1. Edinburgh: Churchill Livingstone, 2004: 229-260.

         (51)                            IF: 1.865               Sectie(s): XI
Nieweg OE; Tanis PJ. Letter to the editor concerning 'intradermal radioisotope injection optimises sentinel lymph node identification in breast cancer' [letter]. Eur J Surg Oncol 2004; 30(6):708-709.

         (52)                            IF: geen                Sectie(s): XI
Nieweg OE; Hoekstra HJ; Marck KW; Van Rijk MC; Kroon BBR. [Important prognostic significance of a sentinel-node biopsy in patients with malignant melanoma]
Belangrijke prognostische betekenis van schildwachtklierbiopsie bij patienten met maligne melanoom. Ned Tijdschr Geneeskd 2004; 148(35):1749-1750.

         (53)                                                    Sectie(s): XI
Noorda EM. Indications and results of isolated limb perfusion. Amsterdam: University of Amsterdam, 2004 [Dissertation].

         (54)                            IF: 3.574               Sectie(s): XI
Noorda EM; Vrouenraets BC; Nieweg OE; Van Coevorden F; Kroon BBR. Isolated Limb Perfusion: What Is the Evidence for Its Use? Ann Surg Oncol 2004; 11:837-845.

         (55)                            IF: 3.574               Sectie(s): XI
Noorda EM; Takkenberg B; Vrouenraets BC; Nieweg OE; Van Geel BN; Eggermont AMM; Hart GAM; Kroon BBR. Isolated limb perfusion prolongs the limb recurrence-free interval after several episodes of excisional surgery for locoregional recurrent melanoma. Ann Surg Oncol 2004; 11(5):491-499.

         (56)                            IF: 2.753               Sectie(s): XI
Noorda EM; Vrouenraets BC; Nieweg OE; Van Geel BN; Eggermont AMM; Kroon BBR. Isolated limb perfusion for unresectable melanoma of the extremities. Arch Surg 2004; 139(11):1237-1242.

         (57)                            IF: geen                Sectie(s): XI
Nunnink CJM; Van Boven H; Van Coevorden F; Oerlemans SH; Meinhardt W. Een bijzondere presentatie van een ductaal prostaatcarcinoom. Ned Tijdschr Urol 2004; 12:47-49.

         (58)                                                    Sectie(s): XI
O'Brien CJ; Shah JP; Balm AJM. Neck dissection and parotidectomy for melanoma. In: Thompson JF, Morton DL, Kroon BBR, editors. Textbook of melanoma. London: Martin Dunitz, 2004: 296-306.

         (59)                            IF: 3.894               Sectie(s): XI, XII, XIII
Olivier RI; Van Beurden M; Lubsen MAC; Rookus MA; Mooij TM; Van de Vijver MJ; Van 't Veer LJ. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up. Br J Cancer 2004; 90(8):1492-1497.

         (60)                            IF: 4.285               Sectie(s): IX, XI
Pos FJ; Horenblas S; Lebesque J; Moonen L; Schneider C; Sminia P; Bartelink H. Low-dose-rate brachytherapy is superior to high-dose-rate brachytherapy for bladder cancer. Int J Radiat Oncol Biol Phys 2004; 59(3):696-705.

         (61)                            IF: 1.805               Sectie(s): XI, XIII
Postema RJ; Van Velthuysen MLF; Van den Brekel MWM; Balm AJM; Peterse JL. Accuracy of fine-needle aspiration cytology of salivary gland lesions in the netherlands cancer institute. Head Neck 2004; 26(5):418-424.

         (62)                                                    Sectie(s): XI
Ruijter ME; Kroon BBR; Nieweg OE. Maligne tumoren van de huid. In: Klaren AD, Van der Meer CA, editors. Oncologie: handboek voor verpleegkundigen en andere hulpverleners. Houten/Antwerpen: Bohn Stafleu Van Loghum, 2004: 555-579.

         (63)                            IF: 2.932               Sectie(s): XI
Rutgers EJT; Meijnen P; Bonnefoi H. Clinical trials update of the European Organization for Research and Treatment of Cancer Breast Cancer Group. Breast Cancer Res 2004; 6(4):165-169.

         (64)                            IF: geen                Sectie(s): XI
Rutgers EJT. Follow-up care in breast cancer. Expert Rev Anticancer Ther 2004; 4(2):212-218.

         (65)                            IF: 3.694               Sectie(s): XI
Rutgers EJT. Sentinel node procedure in breast carcinoma: a valid tool to omit unnecessary axillary treatment or even more? Eur J Cancer 2004; 40(2):182-186.

         (66)                            IF: 3.772               Sectie(s): XI
Rutgers EJT. Sentinel node micrometastasis in breast cancer [letter]. Br J Surg 2004; 91(10):1241.

         (67)                                                    Sectie(s): XI, XIII
Rutgers EJT; Muller SH; Hoefnagel CA. Use of intraoperative probes in surgical oncology. In: Ell PJ, Gambir SS, editors. Nuclear medicine in clinical diagnosis and treatment, Vol 1. Third edition. Edinburgh: Churchill Livingstone, 2004: 217-227.

         (68)                            IF: 1.865               Sectie(s): XI, XIII
Rutgers EJT; Peterse JL. The continued utility of needle localised biopsy for non-palpable breast lesion [letter]. Eur J Surg Oncol 2004; 30:907-908.

         (69)                                                    Sectie(s): XI
Schraffordt Koops H; Lejeune FJ; Kroon BBR; Klaase JM; Hoekstra HJ. Isolated limb perfusion for melanoma: technical aspects. In: Thompson JF, Morton DL, Kroon BBR, editors. Textbook of melanoma. London: Martin Dunitz, 2004: 404-409.

         (70)                            IF: 1.629               Sectie(s): XI
Strackee SD; Kroon FH; Spierings PT; Jaspers JE. Development of a modeling and osteotomy jig system for reconstruction of the mandible with a free vascularized fibula flap. Plast Reconstr Surg 2004; 114(7):1851-1858.

         (71)                            IF: 1.805               Sectie(s): XI
Terhaard CHJ; Lubsen H; Van der Tweel I; Hilgers FJM; Eijkenboom WMH; Marres HAM; Tjho-Heslinga RE; De Jong JMA; Roodenburg JLN. Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch head and neck oncology cooperative group. Head Neck 2004; 26(8):681-692.

         (72)                                                    Sectie(s): XI
Thompson JF; Morton DL; Kroon BBR. Textbook of Melanoma. London: Martin Dunitz, 2004.

         (73)                            IF: 3.324               Sectie(s): XIII, XI
Valdés Olmos RA; Horenblas S; Kartachova M; Hoefnagel CA; Sivro F; Baars PC. 99mTc-labelled heat-denatured erythrocyte SPET-CT matching to differentiate accessory spleen from tumour recurrence. Eur J Nucl Med Mol Imaging 2004; 31(1):150.

         (74)                            IF: 3.278               Sectie(s): XI
Van Andel G; Visser AP; Zwinderman AH; Hulshof MCCM; Horenblas S; Kurth KH. A prospective longitudinal study comparing the impact of external radiation therapy with radical prostatectomy on health related quality of life (HRQOL) in prostate cancer patients. Prostate 2004; 58(4):354-365.

         (75)                            IF: 0.813               Sectie(s): XI
Van As CJ; Op de Coul BMR; Eysholdt U; Hilgers FJM. Value of digital high-speed endoscopy in addition to videofluoroscopic imaging of the neoglottis in tracheoesophageal speech. Acta Otolaryngol 2004; 124(1):82-89.

         (76)                            IF: 3.574               Sectie(s): XI
Van Dalen T; Hennipman A; Van Coevorden F; Hoekstra HJ; Van Geel BN; Slootweg P; Albus-Lutter CF; Brennan MF; Singer S. Evaluation of a clinically applicable post-surgical classification system for primary retroperitoneal soft-tissue sarcoma. Ann Surg Oncol 2004; 11(5):483-490.

         (77)                            IF: geen                Sectie(s): XI
Van de Pol M; Levendag PC; De Bree RR; Huib FJ; Smeele LE; Nijdam WM; Jansen PP; Meeuwis CA; Leemans CR. Radical radiotherapy compared with surgery for advanced squamous cell carcinoma of the base of tongue. Brachytherapy 2004; 3(2):78-86.

         (78)                            IF: 4.017               Sectie(s): XI, XIII, X, IX, BM
Van den Broek GB; Rasch CR; Pameijer FA; Peter E; Van den Brekel MWM; Tan IB; Schornagel JH; De Bois JA; Zijp LJ; Balm AJM. Pretreatment probability model for predicting outcome after intraarterial chemoradiation for advanced head and neck carcinoma. Cancer 2004; 101:1809-1817.

         (79)                            IF: 2.247               Sectie(s): XI
Van der Poel HG. Smart drugs in prostate cancer. Eur Urol 2004; 45(1):1-17.

         (80)                            IF: 3.297               Sectie(s): XI
Van der Poel HG. Mammalian target of rapamycin and 3-phosphatidylinositol 3-kinase pathway inhibition enhances growth inhibition of transforming growth factor-beta1 in prostate cancer cells.